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ABSTRACT OF THE THESIS 
DEVELOPMENT AND EVALUATION OF A CATHETER DELIVERABLE 
ARTIFICIAL AORTIC HEART VALVE PROSTHESIS AND DELIVERY SYSTEM 
by 
Thomas Edward Claiborne. III 
Florida International University, 2008 
Miami. Florida 
Professor Richard T. Schoephoerster, Major Professor 
Currently, malfunctioning heart valves are replaced via highly invasive and costly 
open-heart procedures. A new alternative approach is a catheter deliverable or 
percutaneous heart valve. Current PHV prototypes utilize fixed animal tissue as valves. 
This research investigated the feasibility of an artificial PHV and the development of a 
delivery system. A left hea11 simulator and a tensile tester were used to characterize the 
hydrodynamics and mechanics of a novel artificial PHV. Test results showed equal or 
better in vitro hydrodynamic performance when compared to a St. Jude mechanical valve 
and an Edwards-Sapien PHV, with a mean pressure drop of <15 mmHg and a mean 
regurgitation of <5%. The PHV's exceeded requirements for fixation and radial force. 
The 24 F delivery system successfully delivered and deployed a PHV. The work 
described herein proves the feasibility of an artificial PHV and delivery system and 
justifies further investigation into its design and function. 
Vi 
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1. INTRODUCTION 
Commercially available heart valve prosthetics fall into one of two categories; 
tissue (biologic) and mechanical. ·rhe usc of mechanical valves began on September 2 L 
1960 with the first human implantation of the ball-in-cage S'tarr-Edward'i valve. [1] In 
1979 a report describing the first human implantation of the St. Jude bileaflet mechanical 
valve was published by Emery eta!. [2] St. Jude's current model is shown in figure Land 
it remains the most popular valve prosthesis on the market today. [3,41 
Figure 1: St. Jude Bileaf1et Mechanical Valve. Image from 
http:/ /www.sj m.com/index.aspx. 
However, mechanical valves have remained largely unchanged for the past two 
decades. Mechanical valves are primarily composed of metal alloy frames and pyrolitic 
carbon leaflets. Approximately 80% of implanted valves are mechanical bileatlet valves. 
Mechanical valves are highly durable, with life spans > 15 years in vivo. but they are 
thrombogenic and recipients require lifetime anticoagulant drug therapy, hence they arc 
at risk for bleeding disorders. [3] A recent study found the primary failure modes of 
mechanical valves to be thromboembolism and endocarditis. [5] However, another recent 
study of "middle aged'' patients, of ages 50-65 years, concluded that mechanical valve 
1 
prosthetics remain the best choice for heart valve replacement for that particular 
population in spite of the associated risks. [ 6] 
In 1970 the Hancock porcine aortic valve was introduced to the market, which is 
now manufactured by Medtronic. [3] The Carpentier-Edwards pericardia! tissue valve 
followed suit in 1976. [1] Edwards' current model is shown in figure 2. 
Figure 2: Carpentier-Edwards Perimount Magna pericardia! valve. Image from 
http:/ /w'lvw. edwards. com/products/heartval ves/magna. htm. 
Like mechanical valves, only incremental progress has been made since, e.g. the 
tissue fixation process has improved and extended the average usable life of tissue valves 
to 10 years or more. [3, 7] Tissue valves are typically composed of chemically fixed 
xenografts, specifically, porcine or bovine tissue fixed with glutaraldehyde. The fixing 
chemical cross-links the collagen fibers in the tissue providing strength, flexibility, and 
the prevention of autolysis. Additionally, the chemical treatment reduces antigenicity. 
The result is non-reactive dead tissue that is flexible and preserved for storage. Patients 
who receive tissue valves do not require long-term anticoagulant drug therapy, but 
generally the xenograft tissue begins to degrade via calcification and wear after about 10 
years in vivo. [3] Therefore, their use is typically reserved for patients over the age of 65. 
2 
[ 6] Furthem1ore, a recent study found that bovine pericardia! tissue valves were about 7% 
more durable than porcine tissue valves. [7] However, in generaL the in vivo life 
expectancy of both mechanical and tissue valve prosthetics is dependent upon the 
individual patient's overall health. [4,6] Moreover, the degradation of tissue valves is age 
dependent due to the decreasing metabolism of calcium in aging patients. [6] 
Overall, the implantation of mechanical and tissue valves has been safe and 
effective. The mortality rate for all open-heart valve replacement procedures is estimated 
to be 2-5%. Huwever, the mortality rate for aortic valve surgery is reported to be 17% 
and as high as 18% in octogenarians. [8] Furthermore, open-heart surgery is a highly 
invasive and costly procedure that requires the use of a cardiopulmonary bypass machine 
among others. The average post-procedural hospital stay is 1-2 weeks, including 2-3 
days in intensive care, and the recovery time varies from a few weeks to several months. 
As a result patients are at risk for bleeding. stroke. arrhythmias, death, kidney failure, 
myocardial infarction, medication reactions, breathing difficulty, post-operative 
confusion, and infection. [9] Moreover, the ideal heart valve prosthesis does not exist. 
Therefore. shortcomings remain to be solved in improving the design of prosthetic heart 
valves, e.g. hemocompatibility, durability. implantation method, and hemodynamics. [2, 
26] Hence. there exists ample opportunity to find solutions to these issues. Additionally. 
the trend in cardiovascular interventional medicine in the last decade has been towards 
minimally invasive procedures. rs1 The research proposed here follows that trend 
logically by building upon the work of other researchers in the development of catheter 
deliverable heart valve prosthetics. also known as percutaneous heart valves (PHV). In 
theory, such prosthetics would eventually eliminate most of the risk and cost associated 
3 
with open-heart procedures, and supplant open-heart surgery as the gold standard for 
heart valve replacement. 
2. SIGNIFICANCE 
Cardiovascular disease is the number one killer of all Americans and is rapidly 
rising around the globe. The heart is arguably the most amazing organ in the human 
body. It is a life sustaining electromechanical pump that begins beating during the first 
trimester of fetal development in the mother's womb and does not stop until death. The 
heart beats an average of 100,000 times per day. In the average lifetime it will beat more 
than 2.5 billion times. Failure or impairment of its function can have dire consequences 
including death. An estimated one in three Americans suffers from cardiovascular 
disease, and it is the cause of almost 60% of all American deaths annually. Americans 
will spend an estimated $430 billion in 2007 treating cardiovascular disease. By 
comparison only 44% of that amount of money will be spent treating all cancers. [8] 
Moreover, the world market for heart valve prosthetics is near $1 billion. [ 1] 
The aortic valve generally has two modes of failure; stenosis and insufficiency. 
Stenosis is a reduction in the area of the valve orifice, and insufficiency is a reduction in 
the valve's ability to stop backward blood flow. A diseased valve usually exhibits some 
degree of both failure modes. [ 1 0] However, aortic valve stenosis is the most common 
form of valve disease in the developed world, and an estimated 2-4% of people over the 
age of 65 are affected. [65] Stenosis is typically caused by a congenital defect, 
calcification, commissural fusion, or fibrosis; any of which can also cause insufficiency. 
Insufficiency alone is typically caused by rheumatic heart disease or aortic root dilatation. 
4 
[10] In 2002 the estimated mortality rate for heart valve disease in the U.S. was 20-44%, 
while the estimated mortality rate for aortic valve disease was 25-54%. The prevalence 
of left heart valve disease is estimated to be 1-2% of the American population. Overall, 
an estimated 99,000 heart valve procedures were performed in the U.S. in 2004, but there 
are approximately 300,000 pcrfonned in the developed world annually. The average cost 
of a heart replacement procedure was about $120,000 in 2005. [8] Therefore, the 
development of treatment modalities for heart valve disease remains a significant public 
health issue in the United States of America. 
3. BACKGROUND 
3.1. ANATOMY AND PHYSIOLOGY 
A thorough understanding of the path of blood flow through the heart is necessary 
because the four heart valves are the structures that control the direction of blood flow. 
Figure 3 illustrates heart anatomy. 
Oxygen poor blood returning from the venous system (or reservoir. which holds 
67% of blood volume) enters the right atrium of the heart via large low pressure ( <5 
mmHg) veins called the inferior and superior vena cava. Once filled, the right atrium 
~eakly contracts creating a pressure gradient across the tricuspid valve separating the 
right atrium and right ventricle. Then the tricuspid valve opens and blood flows into the 
right ventricle. The right ventricle is a low-pressure relatively weak thin-walled crescent-
shaped chamber that functions like a bellows stoking a fire. When the pressure in the 
right ventricle exceeds the pressure in the right atrium the tricuspid valve closes, and the 
right ventricle contracts creating a pressure gradient across the pulmonary valve. 
5 
Figure 3: Anatomy and blood flow path in the human heart. Frontal plane cross-section 
is shown. Image from 
http:/!vvww.bg.ic.ac.uk/Staff/khparker/homepage/BSc_lectures/2002/Heart_anatomy.jpg 
Then the pulmonary valve opens and blood is pumped into the pulmonary artery and on 
to the lungs. The nonnal mean pressure in the pulmonary circuit is 10 mmHg. The 
nomenclature of the pulmonary circuit appears opposite to that of all other vascular 
terminology due to its unique functionality, i.e. the pulmonary artery is the only artery in 
6 
the body which carries oxygen poor blood, and the pulmonary veins are the only veins in 
the human body which carry oxygen rich blood. The applicable rule is that arteries move 
blood away from the heart and veins move blood toward the heart. [ 11] 
Likewise, oxygen rich blood retuming from the lungs enters the left atrium via 
two large vessels called the pulmonary veins. The left atrium contracts raising the 
pressure therein, and when the left atrial pressure is greater than the pressure in the left 
ventricle, the bicuspid mitral valve opens and blood flows into the left ventricle. The left 
ventricle is a strong high-pressure thick-walled conical-shaped chamber that functions 
like a fist wringing a wet towel. When the pressure in the left ventricle becomes greater 
than the pressure in the left atrium the mitral valve closes and the left ventricle contracts. 
Then the pressure in the left ventricle rises above the pressure in the aorta, the largest 
artery in the body, the aortic valve opens and the blood is pumped out of the left ventricle 
and into the aortic root and on to the organs and tissues. The arterial system has a normal 
mean pressure of 90 mmHg and contains about 11% of the total blood volume. Once the 
pressure in the aorta exceeds the pressure in the left ventricle the aortic valve closes and 
blood flows into the two coronary arteries located inside the left and right sinuses of 
Valsalva to feed the myocardium. The sinuses are located just above the aortic valve in 
the aortic root. The period of atrial contraction and ventricular filling is called diastole, 
and the period of atrial filling and ventricular contraction is called systole. The normal 
arterial blood pressure is written as systolic pressure over diastolic pressure and is about 
120/80 mmHg. The period of greatest stress on the aortic valve is when it is closed 
bearing the load of arterial diastolic pressure. [3, 11] 
7 
The special anatomical arrangement of tissues in the amiic valve leaflets is the 
source of their ability to function for an entire lifetime. Closely modeling the natural 
leaflet tissue structure may be the key to creating a more durable artificial aortic PHV. 
The leat1ets of the aortic valve are hemispherical in shape and extend from the base of 
each ofthree aortic sinuses, as shown in figures 4 and 5. 
of 
at 
ot 
Valve leaf~t 
Figure- 2.1-14 Diallr<l!Jl nf !he :1nnic '3ln:. L>\ l lhe !X>'ition nf the :1orta at ha<e of the :;bcending aorw is 
indicated.{ Bl Th<" "I'I'<'>Hance ,,r th~ three J<,;tfkts nf th<: annie· 'aln· "h<:n llh' nor!;> is cut orwn and spr.oild 0111. fl<tt. 
(C'ormack D H. ]J<JR7]. !9th t><11 Phila<h:lphia: lB. Uppml.'<.>ll) 
Figure 4: Diagram of the aortic valve. Image from 
http:/ /connection.lww.com/Products/porth 7 e/Ch23 .asp. 
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Figure 5: Dissected porcine aortic valve by Claiborne. Frontal plane cross-section 
shown. 
The aortic valve functions as a collapsing cylindrical tube. The leaflets do not 
simply swing open and closed as a door on a hinge. The leaflets are composed of three 
tissue layers; the lamina fibrosa, lamina spongiosa, and lamina ventricularis. 
Additionally. endothelium covers the entire surface of the leatlets. The lamina fibrosa is 
a dense collagenous tissue on the aortic surface of the leaflets which provides structural 
strength and integrity. The fibers of the lamina fibrosa are aligned mainly in a 
circumferential direction which conelates to the stress concentrations in the leaflets 
during diastole. The surface of the lamina fibrosa is ridged like a gathered sheet of cloth. 
The lamina spongiosa is the middle layer of the leaflets and is a loose matrix composed 
mainly of glycosaminoglycans (large proteins that attract \Vater to form a gel) and water. 
One proposed hypothesis concerning the function of the spongiosa is that it dampens 
vibrations in the lea11ets during the cycle of opening and closing. Another hypothesis 
suggests that the lamina spongiosa reduces friction in the leaflets by allowing the 
outern1ost layers to slide over one another during the opening and closing cycle. Both 
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mechanisms would serve to increase the longevity of the valve. In contrast to the lamina 
fibrosa, the lamina ventricularis is a thinner, weaker, and smooth collagenous tissue on 
the ventricular surface of the leaflets. The function of the smooth surface is thought to 
help maintain laminar blood flow during systole. The coaptation surface of the leaflet 
edges is called the lunula. The lunula is thought to aid in the distribution of the closing 
forces of the valve as well as forming a tight closure seal. The base of the leaflets is 
attached to a fibrous band in the amiic root wall called the annulus. The aortic root and 
annulus are dynamic structures during the cardiac cycle, i.e. they expand and contract as 
well as move proximally and distally. This movement is impaired by fixed diameter 
aortic valve prosthetics and may contribute to early prosthetic failure. [1 0] 
3.2. CARDIAC WORK 
When one or more valves are defective the workload on the heart is increased, 
and blood flow to and from organs and tissues can be impaired. Cardiac work (W) can be 
calculated as: 
Equation 1: W=L\P*SV 
In equation 1 AP is the pressure ditTerence from systole to diastole and SV is the stroke 
volume or volume of blood ejected from the left ventricle during systole. Concomitant 
acute or chronic negative health changes can occur as a result. For example, aortic valve 
insufficiency increases SV, which in turn increases the cardiac workload. Over time the 
left ventricle will dilate due to the volume overload and its walls will become thinner 
leading to decreased contractility and hemi failure. [3] Hence, aortic valve disease is 
commonly associated with heart failure. [8] 
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3.3. WINDKESSEL EFFECT 
The aorta's ability to expand and contract like an elastic tube aids blood flow to 
the coronary arteries and to do,vnstream aor1ic ar1erial branch vessels. This elastic recoil 
also aids in aortic valve closure during diastole. The arteries' capacity to store energy is 
referred to as the fVindkessel efTect: this can be modeled as a simple parallel resistor-
capacitor circuit as shovvn in figure 6 and equations 2-4: 
K 
r 
Figure 6: Electrical analog of a two-element Windkessel modeL where current (I) is a 
function of time (t) and is equivalent to flow rate (Q(f)), capacitance (K) is equivalent to 
compliance (C), voltage (v) is equivalent to pressure (P), and electrical resistance (r) is 
equivalent to vascular resistance (R). 
Equation 2: Two-element Windkessel Model: Q(t)- ~ = C d: 
Equation 3: Systolic Solution: 
I t \ 
-; -- I 
p(t) = RQ0 - (RQ0 - Po )e \/1( 1 
l-1 
-- ---
Equation 4: Diastolic solution: p(t) =Pre lit 
In equation 3, Po is mean diastolic pressure, Q0 is mean flow rate (ml/s) and is 
constant, R is resistance (PRU), and C is compliance (ml/mmHg). In equation 4 Pn is the 
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mean diastolic pressure. Blood vessel resistance can be expressed as the ratio of pressure 
drop to flow rate and is analogous to Ohm 's Law: 
Equation 5: R= ~p/Q 
The units of resistance are peripheral resistance units, where l PRU=l mmHg/ml/s. 
Normal resting vascular resistance is about 1 PRU. Vascular compliance can be 
expressed as ratio of volume change to pressure change in the blood vessel: 
Equation 6: C=!'~v/L"1p 
The Windkessel model can be used to calculate resistance and compliance values 
using P and Q data recorded during in vitro valve testing. [3] However, the equation for 
compliance (mmHg- 1) specified in ISO 5840:2005(E) will be utilized in this research: 
In equation 7, p2 is systolic pressure and p1 is diastolic pressure and d1 and d2 are the 
corresponding vessel diameters. A low compliance value would be 0.09 and a high 
compliance value would be 0.32. [91] 
3.4. HEMODYNAMICS 
An understanding of fundamental hemodynamics is essential in the design of 
heart valve prosthetics. Whole blood is considered to be an incompressible Casson fluid, 
meaning that blood exhibits a small yield stress when a shear stress is applied to a 
discrete static volume of blood. The viscosity of blood decreases nonlinearly as the 
applied shear stress increases, i.e. blood is a shear thinning fluid. Therefore, blood tends 
to coagulate at low shear rates. The constitutive Casson equation is: 
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Equation 8: 
In equation 7 T is the shear stress. Ty is the yield stress, kc is Casson blood viscosity 
coefficient, and dy/dt is the shear rate. This information informs valve designers that low 
velocity blood t1ow and recirculation zones near the valve prosthesis should be 
minimized to prevent thrombosis. [3 j 
Blood f10\v in veins and capillaries is considered to be steady, while blood t1ow in 
the aorta and arteries is considered to be unsteady. Blood f1ow in the aorta is not 
considered to be fully developed because the calculated entrance length (L) is greater 
than the length of the aorta: 
Equation 9: L=0.06*D*Re 
In equation 8 Dis the vessel diameter (em) andRe is the Reynold~· number: 
Equation 10: Re=(pVD)/~t 
In equation 9, pis blood density (1.06 glee), Vis blood velocity (cm/s), and~ is blood 
viscosity (3.5 cP). The Reynolds number is a non-dimensional ratio of inertial forces to 
viscous forces. At ]0\v Reynolds numbers viscous forces dominate and at high Reynolds 
numbers inertial forces dominate. Typically. turbulent fluid flow is characterized as 
having a Re>4000. However, in the aortic root and arch the Re>5000, but the flow is 
mostly laminar due to the curvature of the aorta. the development of Dean Vortices, and 
the pulsatile nature of the flow. These factors prevent blood cell damage that would be 
caused by the high shear stresses of fully turbulent flow. The non-dimensional Dean 
number is: 
Equation 11: ND=Re(Rv/Rc), 
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In equation 10 Rv is the vessel radius and Rc is the radius of vessel curvature. The 
magnitude of the Dean number is directly proportional to the magnitude of the eftects of 
vortices or inertia. [3] 
Another useful parameter is the Womersley number: 
Equation 12: a=(DI2)(wpl)l)l!2 
In equation 11 D is the vessel diameter, co is the frequency of fluid oscillation (heart rate), 
p is blood density, and p. is blood viscosity. The Womersley number is the unsteady 
version of the Reynolds number and can more accurately describe the flow regime of 
pulsatile flow. In the amia a=18.6 when HR=70 bpm. Like the Reynolds number. a 
larger a means that oscillatory inertia forces dominate and a smaller a means that viscous 
forces dominate. [3] 
The classic model of steady Nev..ionian fluid flow· through a uniform rigid tube is 
called the lfagen-Poiseuille equation: 
Equation 13: .6.p=(l28~tLQ)/(nD4) 
In equation 12 p is pressure, !l is blood viscosity, L is vessel length. Q is flow rate, and D 
is vessel diameter. This equation is derived from the famous Navier-Stokes equations. It 
is important to note that substituting equation 5 into equation 12 shows that vascular 
resistance is inversely proportional to the diameter of the blood vessel raised to the fourth 
power, i.e. changes in blood vessel diameter have a dramatic effect on changes in 
vascular resistance and blood pressure. This explains why most hypertension treatments 
include vasodilating drugs. [3] 
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When a traditional prosthetic valve is implanted invariably a stenosis is caused in 
the aortic root. Combining the conservation of energy and conservation of mass 
equations yields a model for pressure drop across a stenotic valve prosthesis: 
Equation 14: p1-p2= { (pQ2)/2} * { 1 /(A 2 0C2 ct)} 
In this model A is the cross-sectional area at a given position. Furthermore, position 1 is 
upstream from the valve, position 0 is the surface of the valve, and position 2 is the vena 
contracta downstream from the valve. The vena contracta is an area of flow issuing forth 
from the valve orifice wherein the streamlines continue to narrow as fluid t1ow moves 
dov.nstream from the valve orifice. The point of minimal cross-sectional area of forward 
moving flow is called the vena contracta. The discharge coefficient is: 
Equation 15: Cct=(CcCv)/{1-C2v(A0/A 1)} 112 
The contraction coefficient is: 
Equation 16: Cc=A2/ Ao 
The velocity coefficient is: 
Equation 17: Cv=V 2actuatfV 2idcal 
The ideal velocity is: 
Equation 18: 
The etiective orifice area is given by the Gorlin Equation: 
Equation 19: EOA=Ao =(Qmear/Cd ){p/(2~p)} 
The landmark Gorlin equation published in 1951 is still used clinically today to calculate 
valve area. [3,75] Ilo\\·ever, the equation for effective orifice area (cm2) specified in ISO 
5840:2005(E) will be utilized for this research: 
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Equation 20: Q/1\/S =---
51.6 ~~}J 
~ p 
In equation 19, Q (ml/s) is the root-mean-square of forward flow. £\p (mmHg) is the 
pressure drop across the valve during forward flow, p (g/ml) is the density of the test 
fluid, and 51.6 is a constant that allows the units to be correct. [91] 
Clinically relevant parameters may also be calculated when designing and testing 
heart valve prosthetics. Stroke volume is given by the equation: 
Equation 21: SV=EDV -ESV 
In equation 19 EDV is the end diastolic volume or the maximum ventricular volume prior 
to contraction and ESV is the end systolic volume or the amount of blood in the 
ventricles at the instant of maximal contraction. Normal resting stroke volume is about 
90 ml/beat. Cardiac output is the time averaged blood flow rate: 
Equation 22: CO=SV x liR 
Nonnal resting cardiac output is 5 Llmin. Mean arterial pressure is defined as: 
Equation 23: MAP=(ps+2pJ)/3 
In equation 21 Ps is systolic pressure and Pd is diastolic pressure. Nomml resting mean 
arterial pressure is about 95 mmHg. Cardiac index relates cardiac output to body surface 
area (BSA): 
Equation 24: CI=CO/BSA 
The body is considered to be a cylinder of diameter d and height h when calculating 
BSA: 
Equation 25: BSA=ndh+2n:d2 
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Normal resting cardiac index is about 3.25 Llmin/m2. Ejection fraction 1s used to 
quantify the general health ofthe heart: 
Equation 26: E1=SV /EDV 
Nom1al resting Er is above 55%. A valve designer can optimize the hemodynamics of his 
valve prosthesis by employing these analytical equations. [3] 
3.5. SOLID MECHANICS 
A basic understanding of solid mechanics is also useful in valve design. The core 
relationship often utilized when studying solid material behavior is known as Hooke's 
Law: 
Equation 27: a=Ec 
In equation 25 a is stress (t(xce/area), E is Young's modulus (elastic material constant), 
and£ is strain. Strain is a non-dimensional number equal to the change in loaded material 
length divided by the material's unloaded original length. Generally, stress is plotted as a 
function of strain and the slope of the line is equal to Young's elastic material modulus. 
[3] 
Large blood vessels, such as the aorta, can be modeled as thin-walled high-
pressure tubes \Vhere the circumferential wall stress, called hoop stress, is calculated as: 
Equation 28: a 0=(pR)It 
In equation 26 p is transmural pressure, i.e. the difference between the pressure inside 
and outside the vesseL R is the vessel radius. and t is the vessel wall thickness. The 
subscript e denotes the circumferential direction when polar coordinates (r, e. z) are 
specified. Moreover, the axial or longitudinal vessel wall stress is defined as: 
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Equation 29: crz=(pR)/(2t) 
The radial stress is simply equal to the transmural pressure gradient: 
Equation 30: Cir=Pinsidc-Poutsidt· [3] 
3.6. VALVE DISEASE CLASSIFICATIONS 
Clinical valve disease classifications are ubiquitous 111 literature; therefore a 
knowledge and context of their meaning is essential to understanding medical reports. 
Table l shows the AC'C/AHA valve disease qualitative and quantitative scores. [68] 
Defect Indicator Mild Moderate Severe 
Aortic Stenosis Jet Velocity (m/s) <3 3 to 4 >4 
Mean Gradient (mmHg) <25 25 to 40 >40 
Valve Area (cm2) >1.5 1.0 to 1.5 <1.0 
Aortic Regurgitation Regurgitant Volume (ml/beat) <30 30 to 59 >= 60 
Quantitative Regurgitant Fraction(%) <30 30 to 49 >=50 
Reguritant Orifice Area (cm2) <0.10 0 10 to 0.29 >= 0.30 
Qualitative 1+ 2+ 3+ to 4+ 
Table 1: ACC/ AliA Aortic Valve Disease Classifications 
3.7. MATERIALS 
3.7.1. NITINOL 
Nitinol is an alloy composed of nickel and titanium in a near 50:50 ratio. Super-
elasticity is defined as full elastic recovery after more than 10% strain. Nitinol's super-
elasticity comes from the mechanism by which it elastically deforms. It undergoes a 
phase transformation when a stress is applied changing from a cubic austenitic crystal 
structure to a monoclinic martensitic structure. When it is unloaded it changes back to 
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cubic austenite. Its mechanical characteristics are highly temperature dependent, but 
body temperature (3TC) is within its super-elastic range. [59.60,62] 
It is biocompatible due to its self-passivating ability to form a stable oxide 
surface. Ho\vever. studies have shown that surface finish can have dramatic effects on 
Nitinol' s corrosion resistance and mechanical properties. In fact electropolished Nitinol 
releases less nickel in vivo, forms a stable titanium-oxide surface layer, and resists 
corrosion better than mechanically polished or unpolished Nitinol. [60,62] 
Furthermore, studies have shown that over-sizing the unloaded diameter of a 
Nitinol stent by at least 20% places the radial force and fixation force within the blood 
vessel at levels required to prevent migration (without an in situ valve). Moreover, the 
number of wire bends and the diameter of the w·ire are proportional to the stent's ability 
to resist collapse, i.e. the radial force exerted by a stent increases with increasing number 
of wire turns and increasing wire diameter. Furthem1ore. Nitinol is entirely cmsh 
resistant, i.e. it can be crushed flat and it will fully recover to its unloaded shape. 
According to Duerig et al. 2000 it is preferable to characterize Nitinol stent performance 
in terms of"'hoop stiffness" because it reflects the stent's ability to resist diameter loss: 
Equation 31: ko=Fo/ L'lD 
In equation 30 k0 is the hoop stiffness, F0 is the hoop force and D is the vessel diameter in 
polar coordinates. Hoop force can be calculated from equation 26, and L'lD can be 
measured in vitro. It is worth noting that k0 is equal to the inverse of compliance 
(equation 5). [59,60] 
Heat treating (annealing) Nitinol can alter its mechanical properties by raising its 
austenitic finish temperature (Ar). This means that at temperatures below Ar a Nitinol 
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stent can be plastically deformed (called Martensitic or Body Temperature Nitinol), and 
once it encounters temperatures above its Ar it will become super-elastic agam. 
Typically, Nitinol vascular stents are treated so that they have an Ar = 2WC. 
Additionally, for each degree that Ar is below body temperature, the stiffness of Nitinol 
increases by approximately 4 N/mm2• [60] 
A Nitinol stent can closely match the aortic root compliance, i.e. expanding and 
contracting, as evidenced by the stress-strain curve for Nitinol, which resembles that of 
human connective tissue. Furthermore, in vivo it produces a low chronic outward force 
(COF) that is believed to help maintain a patent vascular lumen. Moreover, it exhibits 
''biased stiffness'" in vivo, i.e. when a crushing force is applied the stiffness of the stent 
quickly increases from the steady state COF to its original elastic strain plateau. Under 
cyclic loading Nitinol appears to become stress saturated after about 60 cycles, and then 
its elastic response becomes constant albeit slightly less than pre-implantation, i.e. the 
stent stiffens slightly. [60,62] 
In terms of imaging, it is less non-ferromagnetic than stainless steel and produces 
low magnetic resonance artifact similar to pure titanium, and it is about equal to stainless 
steel in X-ray imaging. [60.62] 
In summary, Nitinol appears to be the best choice of material available for the 
fabrication of a PHV, but it is expensive, relatively rare, and its properties are highly 
process and temperature dependent. It requires a skilled metallurgist to perform proper 
processing in order to achieve the desired properties. Therefore. Nitinol has been 
reserved for the final PHV design in this research. [61 ,87,88,89] 
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3.7.2. STAIN LESS STEEL 
In contrast, stainless steel is narrowly elastic ( < 1% strain), highly malleable, and 
about 80% more rigid than Nitinol. Therefore. it does not require annealing for shape 
fonning, and it cannot match vascular compliance. Its pnmary advantages are 
availability, relatively low cost, ease of manipulation, and supenor radial stiffness. 
[59,60,62] HO\vevcr, a stent made from stainless steel will require balloon expansion in 
situ, i.e. BA V, which associated with complications such as bleeding, arrhythmia, 
embolism, and other minor complications. [85] Furthermore. initial lab testing has shown 
that plastically deforming or cold working stainless steel wire embrittles the metal via 
strain hardening and can lead to fracture. Stainless steel is widely available in a variety 
of alloys. Generally, higher concentrations of chromium correlate to increased cost, 
increased corrosion resistance and decreased ductility. l59,60,62,86] 
3.7.3. SIBS 
The polymer heart valve promises to be the next generation heart valve prosthesis 
that should eliminate the need for both tissue and mechanical valves. However, polymer 
valve development has been beset \vith complications because a suitable polymer was not 
available. Ongoing research in the Cardiovascular Engineering Center (CVEC) at FIU 
has been investigating a novel super-biostable polymer for heart valve prosthetic 
application called SIBS (poly(styrene-isobutylene-styrene) or SIBS) provided by Innovia, 
LLC, Miami, Florida. The SIBS thermoplastic elastomer is highly corrosion resistant in 
contrast to silicone rubbers and polyurethanes previously investigated for heart valve 
applications. It has excellent biocompatibility and resists degradation in vivo. [94] In the 
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CVEC it has been used to construct a novel trileat1et aortic heart valve prosthesis. The 
valve material developed is comprised of polyester fabric and SIBS. The polyester was 
employed to reinforce SIBS and prevent creep. [58] 
3.8. REGULATORY ISSUES 
Prosthetic heart valves are classified as Class III medical devices by the United 
States Food and Drug Administration (FDA) Center for Devices and Radiological Health 
(CDRH) under the Department of Health and Human Services. In particular, the Code of 
Federal Regulations (CFR) Title 21 section 870.3925 defines heart valve prosthetics and 
their requirements for development. Class III devices are defined in 21 CFR860.3. and 
are essentially anything implantable or life sustaining. The design, testing, and 
performance of heart valve prosthetics are regulated by ISO 5840:2005(E). [91] The FDA 
recognizes the ISO standard as number 014 in their list Recognized Consensus Standards. 
The FDA also has a guidance document entitled '"FDA Replacement Heart Valves Draft 
Guidance, V.S.O". [92] These documents and agencies ensure that minimum performance 
and safety standards are met when developing prosthetic heart valves. 
4. HISTORY AND FEASIBILITY OF PHV'S 
4.1. BEGINNINGS 
Percutaneous heart valve (PHV) prosthetics embody the most significant advance 
in heart valve prosthetic technology in two decades, but it is an idea that has taken some 
time to germinate. The first report of a minimally invasive treatment for aortic valve 
insufficiency was published by Hywel Davies in 1965. [12] The valve, manufactured by 
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U.S. Catheter Co., Glenn Falls, New York. \'.as essentially a parachute tethered to the end 
of a 5 F catheter that was introduced into the descending aorta via peripheral artery 
access. It \vas intended to decrease amiic valve insufficiency so that patients could 
withstand or forgo open-heart valve replacement surgery. Davies reported successful 
tests in dogs. 
Following the \vork of Davies. in 1971 Moulopoulos et al. n:ported the creation 
and testing of similar designs. They fabricated and tested two distinct prototypes. One 
functioned like an umbrella and the other \vas a balloon that was inflated and deflated via 
a machine in synchronization with the cardiac cycle. They tested their prototypes in dogs 
and reported good results with the umbrella design. [13] Interestingly, their balloon-
pump composite mechanism was later developed into a widely employed therapy called 
an intra-aortic balloon pump, \vhich is still used today \vhen acute cardiac support is 
needed. 
In 1976 Phillips et al. followed suit reporting successful animal tests of another 
similar catheter mounted valve which they described as a polyurethane cusp. However, 
the use of catheter mounted valves for the treatment of aortic valve insufficiency did not 
appear to gain wide interest as evidenced by the absence of fmiher reports on the subject. 
[ 14] 
4.2. DETOUR 
In 1984 a new minimally mvas1ve valve therapy. percutaneous balloon aortic 
valvuloplasty (BA V), was presented for the first time by Lababidi et al. for the treatment 
of aortic valve stenosis. [ 15] They reported an overall 69% reduction in the peak systolic 
aortic valve pressure gradient post-BAV. Subsequently, their results prompted wide 
interest in the technique. BA V gained popularity through the 1980's, but interest waned 
through the 1990's because its efficacy was not impressive. Restenosis typically recurred 
within one year ofBAV. Today BAV is used as a palliative therapy for patients awaiting 
valve replacement surgery or those who are not candidates for said procedure. [65] 
4.3. PI-IV'S REINCARNATED 
Percutaneous valve implantation regained interest after the publication of the 
work of Andersen et al. in 1992. [ 16] They \vere the first to describe the design of a true 
untethered PHV. The valve was composed of a porcine aortic valve mounted to two 0.55 
mm stainless steel wire stents connected with 2-0 Merseline sutures. The porcine valve 
was mounted to the stent using 5-0 Prolene sutures. In its collapsed state, the valve was 
12 mm in diameter. The fully expanded diameter of the valve was 32 mm. A 41 F 
catheter was used to deliver the PHV via the abdominal aorta of a pig. Their results were 
not impressive. but they proved the technical feasibility of PHV's. They followed up in 
1993 publishing work detailing in vitro and further animal testing of their valve. [71] 
Conctmently, in 1992, Pavcnik et al. presented the first artificial PHV concept. 
[ 17] The valve was a ball-in-cage design similar to the Starr-Edwards valve; however the 
cage was made from a self-expanding stainless steel stent and wires, and the base or 
annulus was a composite of Lycra spandex and stainless steel wires. The cage featured 
barbs for fixation. The ball was a latex balloon that was filled with a radiopaque 
"prepolymer" which cured in situ. The assembly was delivered in two stages, each by a 
12 F catheter. The animal results confirmed that the design was an absolute failure, 
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which leads one to wonder why in vitro testing of the design did not occur prior to animal 
testing. Perhaps in deference to their early experience, Pavcnik et a!. followed up 12 
years later by presenting a novel bileaflet catheter deliverable venous valve in 2004. [18] 
Moazami et al. followed the work of Andersen and coworkers in 1996 by 
presenting a bovine pericardia! valve mounted to 0.020 inch stainless steel wire stent. 
[19] Their in vitro results showed regurgitation of 15% and a transvalvular pressure 
gradient of 15 mmHg with a mean f1ow rate of 3.1 Llmin. They implanted their valve 
into pigs using a 24 F catheter via direct vision through an aortotomy. This technique 
required the use of cardiopulmonary bypass. Their in vivo results were ambiguous. As a 
result, only technical feasibility of their PHV design was proven. 
4.4. TECHNOLOGICAL BOOM 
4.4.1. PULMONARY PHV'S 
The work by pioneers in the 1990's laid the ft1undation for a technological boom 
in beginning of the 21st century. Bonhoeffer et al. catalyzed a rapid precipitation of 
interest in PHV technology with the 2000 publication of their work describing the first 
human implantation of a pulmonary PHV. [20] (Earlier that year they had published work 
describing successful animal trials. [21]) The patient was a 12 year old boy who had a 
Carpentier-Edwards valved conduit connecting the right ventricle to the pulmonary 
artery. The conduit exhibited significant stenosis and insut1iciency that were causing an 
enlargement of the right ventricle. Catheterization vvas performed through the right 
femoral vein, and the valve was implanted into the conduit via an 18 F delivery catheter. 
They reported an uneventful case and a successful outcome. Their valve design was 
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composed of an 18 mm bovine jugular vein segment containing an in situ venous valve 
mounted inside a balloon expandable platinum-iridium alloy stent. Subsequently, their 
pulmonary PHV design, now called Melody shown in figure 7, is in clinical trials with 
Medtronic. 
Figure 7: Medtronic MelodyTM pulmonary PHV. Image from 
http:/ /wVvw .medtronic. com/inti/melody I. 
Lutter ct al. presented two studies detailing the design and animal testing of a 
pulmonary PHV similar to the Bonhoeffer valve. [32,35] Lutter and coworkers attached a 
bovine jugular vein segment with an in situ venous valve to a self-expanding Nitinol 
stent. They delivered the stent into the pulmonary valve position via a 24 F catheter with 
some success and proved the feasibility of their design. They noted that the radial force 
of their stent was 0.1 N at a diameter of 20 mm and 37oC. Additionally, they noted that 
20% oversizing of the stcnt diameter provided sufficient anchoring. They sited stent 
migration in a 12% oversized stent as evidence. 
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Feinstein et al. published a human case report in 2006 wherein they built a 
pulmonary PHV and implanted it into a l 0-month old female. [ 46] Their work is the first 
reported on a patient so young. The valve was composed of a Palmaz stent and a porcine 
valve taken from a Hancock valved conduit. The valve was sutured to the stent using 6-0 
and 7-0 Goretcx and Prolene sutures. It was delivered via a 10 mm catheter through the 
jugular vein. The procedure was a success. and one year out the patient was doing well. 
4.4.2. AORTIC PHV'S 
Another landmark event occurred in 2002 when Cribier et al. repmied the first 
human case of aortic PHV implantation using an antegrade approach. [24] Their valve 
was composed of bovine pericardia! leaflets mounted inside a balloon expandable 
stainless steel stent. The valve was delivered via a 24 F catheter inserted in to the 
femoral vein. The atrial septum was punctured and dilated with a 10 mm balloon. The 
catheter was advanced across the mitral valve and into the aortic valve. They reported a 
70% reduction in the transvalvular pressure gradient. Their design had been developed 
and vetted by Percutaneous Valve Technologies, Inc. of Fort Lee, New Jersey. Currently, 
their valve. now called Sapien (Cribier-Edwards) shown in figure 8, is in clinical trials 
with Edwards Life Sciences. (Subsequently. the first human case of pulmonary valve 
replacement using the Sapien valve was reported by Webb et al. in 2006. [27]) 
Concurrently, Bonhoeffer and Boudjemline published work in 2002 describing an 
altered version of their pulmonary PHV design for use in the aort.ic valve position. [72] 
They reduced the area of tissue coverage on their original PHV so as not to block the 
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coronary ostea, and they added an outer Nitinol stcnt that expanded into the sinuses of 
Valsalva for fixation. 
Figure 8: Edwards Life Sciences SapienTM (Cribier-Edwards) aortic PHV. Image from 
http://www .ed wards.com/ products/percutaneousval ves/ sapienth v. htm. 
As a result the delivery process was carried out in 4 stages: delivery, 
deployment of the Nitinol stent, balloon expansion of the PHV, and removal of the 
balloon and catheter. Unfortunately, the results indicated a failure of their design as 
evidenced by complications such as coronary obstruction, mitral valve interference, and 
PHV insufficiency. Additionally, they experimented with implanting their original 
pulmonary PHV design into the descending aorta. [73] In that publication they reported 
marginal success. 
In 2004 Ferrari et al. presented a novel aortic PHV which was tested in pigs. [28] 
Their design was composed of a porcine pulmonary valve mounted inside a Nitinol stent. 
The stent featured barbs for fixation and the delivery catheter was 25 French. They 
reported favorable results, including no observed damage to the aortic intima caused by 
the stent barbs. However, the in vivo test only lasted six hours and they did not perforrn a 
microscopic examination of the intimal tissue. 
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In 2005 Grube et al. reported the .fin;t human implantation of CoreValve's first 
generation self-expanding aortic PHV shown in figure 9. [29] 
Figure 9: Core Valve's Revalving ' aortic PHV. Image from 
http://wvvw.corevalve.com/products.aspx#. 
The tested valve design was composed of a bovine pericardia! valve mounted 
inside a self-expanding Nitinol stent that was laser cut from a 50 mm long Nitinol tube. 
The iliac artery was exposed via surgical cut-down, and the femoral artery and vein were 
cannulated for extracorporeal circulatory support. They reported a 79% reduction in the 
transvalvular pressure gradient, and a 40% increase in the ejection fraction. No 
regurgitation was found. 
Laborde et al. reported the design and animal testing of a variation on the 
Core Valve PHV in 2005. [43] The valve was composed of the bovine pericardia! tissue 
valve used in the original CoreValve and an assembly ofZ-stents made from Conichrome 
wire, which they claimed had excellent strength. They used 4-0 and 5-0 Polypropylene 
suture to hold the entire assembly together. The PHV could be crimped to 25 F and was 
self-expanding. They implanted the valve into 14 sheep. The design saw the addition of 
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hooks to the proximal end of the stent after it sprang into the left ventricle upon 
deployment. Their results proved the design to be a failure. e.g. the valves migrated post-
deployment and showed significant insuflicicncy. Interestingly. in 2006 they reported a 
human case of original Core Valve implantation. [ 44] It seems that Dr. Laborde had 
entered into a business arrangement with CoreValve at sometime before the publication 
of their 2006 paper. 
Lutter and coworkers published work in 2005 describing the design and testing of 
an aortic PHV. [30] It was composed of a self-expanding Nitinol stent with barbs for 
fixation and either a porcine aortic valve or pericardia! valve. They reported in vitro test 
results of 0 to + 1 regurgitation and less than 7 mmHg transvalvular pressure drop. In 
vivo animal test results were marginally successful with similar hemodynamic value 
reported. 
The first human case of retrograde implantation of an aortic PHV was claimed by 
Paniagua et al. in 2005. [25] Here, PHV means "Paniagua Heart Valve." The entry point 
was the femoral artery accessed via surgical cut-down. and the delivery catheter was 16 
F. They began developing a novel amiic PHV in 1998. They did not provide a detailed 
description of the valve. but it appeared to have been an animal valve mounted inside a 
metal stent. Strangely, from this report it appears that they have focused entirely on the 
valve itself rather than a valve-stent composite device because of a statement that reads, 
"To deliver the device, we used a Cheatham-Platinum ... stent..." Simply testing an 
cxplanted animal valve does not constitute a PHV. Their results seem dubious as well. 
They reported zero transvalvular gradient and regurgitation in this case, as well as in 
animal and in vitro trials. The patient died 5 days post-implantation of undeten11ined 
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causes. Adding to the incredulity, Paniagua erroneously claimed to have been the first to 
perform animal testing of a PHV in June 2000, when Andersen and coworkers were 
clearly first in 1992. However, his claim in the 2005 paper seems to be legitimate. 
In a dubious 2007 study, Fletcher and coworkers reported the in vitro study of a 
PHV. [45] It appears that they did not intend to design a novel PHV, but rather they 
intended to show how a PHV could obstruct the coronary ostea. So they designed and 
built a PHV that did exactly that. It was constructed from a Medtronic cobalt-nickel stent 
and ovine pericardium. Explanted pig hearts served as their in vitro modeL 
4.4.3. ARTIFICIAL PHV'S 
In terms of artificial PI-IV's, Sochman and coworkers have been the pioneers of 
late. They followed the work of Pavcnik et al. and in 2000 reported successful animal 
trials of an artificial aortic PHV. [22] Their valve was composed of a polyurethane coated 
stainless steel disc mounted inside a stainless steel Gianturco Z-stent. They made one 
PHV "cage" with barbs for fixation and one without barbs. The stent and disc were 
delivered separately each by a 10 F catheter. Tetlon suture (5-0) was used to engage and 
lock the disc in place. The PHV was implanted into four dogs. The non-barbed cage did 
not remain fixed and migrated into the ascending aorta. The barbed cage remained where 
deployed but was interfering with the coronary ostea. They reported easy deployment of 
the disc in all locations. Additionally, they reported favorable disc movement. no 
transvalvular pressure gradient, and no macroscopic intimal damage. They followed up 
in 2006 with a revised polymer disc PI IV design that failed outright in animal tests. [23] 
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Webb and coworkers reported the development and testing of a novel PHV design 
in 2004 for use in the pulmonary or aortic position. [27] Their design was unique in that it 
was a coiled Nitinol sheet which contained a bovine pericardia! valve. The delivery 
catheter was 22 F. When the valve was deployed into the vessel it automatically uncoiled 
and retained its maximum expanded diameter via a locking ratchet built into the stent. 
However, the final expansion and locking of the stent ratchet required balloon dilatation 
in vivo. Curiously, they reported the performance of in vitro and animal tests but did not 
include any data. Instead they reported a qualitative analysis coupled with a list of design 
requirements. 
In 2005 Levi et al. reported the design and testing of a bicuspid pulmonary PHV 
intended for use in smaller pediatric patients. [ 42] They called their design a "covered 
stent heart valve" or CSV. The CSV was composed of a modified Palmaz P308 stent 
mounted inside a Goretex vascular graft conduit. Sections of the stent were removed and 
the graft was cut such that two "leaflets" could collapse inside the lumen of the stent. A 
second Goretex conduit was placed over the assembly and was bound to the stent by 6-0 
Prolene sutures. Several variations were built and tested. The delivery catheter ranged in 
size from 7-10 F. In vitro results showed up to 41% regurgitation and transvalvular 
pressure gradients over 300 mmHg at less than 1 Llmin of flow through a 19 mm 
diameter PVC tube with a 16 mm diameter stenosis region for valve placement. In spite 
of the poor in vitro results, the prototypes were tested in vivo by implanting them into the 
descending aorta of pigs, but only qualitative results were reported. 
In 2006 Lutter et al. presented a novel artificial pulmonary PHV design composed 
of a polyurethane trileaflet valve mounted inside a Nitinol stent. [36] No test data 
32 
concerning their design has yet been published. Ho'vvever, polyurethane is well known to 
be an inadequate material for heart valves. 
4.4.4. OTHER CONTRIBUTORS 
Lutter and team have been prolific in studying PHV technology and participating 
clinical trials with Sapien, Melody and Core Valve. [30,31 ,32,33,34,35,36,37,38,39,56] 
They have also been the first to publish work describing the first human cases of 
endovascular laser and water aortic valve ablation. They hypothesize that removal of the 
diseased aortic valve prior to PHV implantation could improve PHV safety and efticacy. 
Additionally, Zajarias et al. reported successfhl coronary catheterization after 
implantation of the Sapien PHV. [74] 
In summary, there have been many contributors to modern PHV technology, but 
BonhoefTer and Cribier (and coworkers) can safely be called the fathers of modern PHV 
technology. Moreover, several private commercial entities are currently developing 
PHV's, but gaining access to their information is not possible due to proprietary 
constraints. 
4.4.5. PROFESSIONAL TENSIONS 
The speed of progress in aortic PHV technology during this decade has caused 
controversy between the rank and file of cardio-thoracic surgeons and interventional 
cardiologists. A 2005 report published by a group of physicians composed of cardio-
thoracic surgeons and interventional cardiologists (notably lacking any PHV inventors) 
was intended to embody an effort to establish cooperation, quell controversy, and create 
clinical standards for the future development of PHV's. [49] First the repm1 established 
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open-heart valve replacement as the ''gold standard". Then it claimed that no PHV trials 
to date had been randomized or controlled, and as a result data had been biased and in 
some cases incomplete. Additionally, it mandated cooperation and collaboration between 
cardiac surgeons and cardiologists. Finally, it outlined several recommendations 
concerning the perfonnance of clinical trials of aortic PHV's. 
In summary, the report recommended that aortic PHV study candidates should be 
symptomatic inoperable patients whose long-term survival is compromised. It speculated 
that such a selection of patients would illuminate short and mid-term durability and the 
safety and efficacy of amtic PHV's. The effectiveness of their effort has yet to be 
proven. 
4.5. PHV CLINICAL OUTCOMES AND COMPLICATIONS 
4.5.1. AORTIC PHV'S 
The development of aortic PHV's has not been without problems. A multicenter 
30-day prospective study of Core Valve implantation in 86 octogenarians was published 
in 2007. [66] The authors reported an overall 88% success rate and a 75% reduction in 
the 30 day mean transvalvular pressure gradient. l-Iowever, they reported a 34% 
occurrence of increase in regurgitation and a 66% occurrence of no change in 
regurgitation post-implantation. The mortality rate was 12%, and the major adverse 
cardiac and cerebral event (MACCE) rate was 26%. Complications reported included 
inaccurate device deployment. perivalvular leakage, stroke, death. and cardiac tamponade 
due to ventricular perforation via the guidewirc. Interventional therapies administered 
during the PHV procedures included BA V, rapid pacing, extracorporeal circulatory 
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support, and total peripheral cardiopulmonary bypass. The delivery catheters in all cases 
were 21 or 18 F and the approach was retrograde via iliac, subclavian or femoral arteries. 
There was no control for the study; therefore conclusions about device efficacy could not 
be drawn. 
A single center study of 33 cases of Sapien PHV implantation into octogenarians 
was reported in 2006. [64] Data from 30-days and 6-months post-implantation were 
evaluated. In terms of procedural approach, 79% were antegrade and 21% were 
retrograde. The antegrade approach had an 85% success rate, and the retrograde 
approach had a 57% success rate. The 30-day mortality rate was 18%, and the 6-month 
mortality rate was 37%. As ofthe date of the publication 33% of the study patients were 
still living. There was an overall reduction in transvalvular pressure gradients of about 
75% and mild to severe regurgitation post-implantation and zero to moderate 
regurgitation at 6-months. The delivery catheter was 24 F in all cases. 
Berry et al. published a case report in 2007 detailing their expenence with 
CoreValve. [51] The patient died during the procedure as a result of a stroke caused by a 
piece of plaque dislodged from the catheter introduction site in the left external iliac 
artery which occluded the left subclavian artery. The delivery catheter was 21 F. This 
case demonstrated the need for rigorous peripheral vascular studies prior to approval of 
aortic PHV trial candidacy. 
4.5.2. PULMONARY PHV'S 
The less dramatic consequences of pulmonary valve failure have allowed 
pulmonary PHV development to outpace aortic PHV development. A 2005 report 
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detailed the clinical outcomes of 59 pulmonary PHV recipients. [67] The study spanned 
36 months. In contrast to the clinical trial participants in aortic PtiV trials, pulmonary 
PHV candidates are generally not critically ill and are pediatric. Study inclusion criteria 
were the presence of a surgically repaired RVOT, symptomatic dysfunction of the 
RVOT, right ventricular hypertension, dilatation or failure, and pulmonary insufficiency. 
In other words, the PHV procedure was not last resort as in the case of aortic PHV's and 
was indeed voluntary. The average study pmiicipant was 16 years old and weighed 56 
kg. 78% ofthem had homograft RVOT's. A 98% initial success rate was reported with 
zero deaths. The results showed a 22% drop in RV pressure, a 41% drop in RVOT 
pressure gradient, and a 27% increase in PA diastolic pressure. Regurgitation was no 
more than mild in all cases. At 36-months 70% of the PHV's were still functioning. 
Complications included stent dislocation from the guide w·ire, homograft dissection via 
balloon oversizing. detachment of the tip of the delivery catheter, local bleeding, in-stent 
stenosis caused by a "hammock effect" in early iterations of the Melody PHV where the 
entire vessel was not sutured to the stent, stent fracture, late stent embolization (9-
months) into the PA, residual stenosis, intravascular hemolysis, and endocarditis. 
Melody PHV stent fracture has become such a concem that a repmi investigating 
its occmTence and risk factors was published in 2007. [54] In a retrospective study of 123 
Melody recipients, there was a 21% rate of stent fracture. Regression analysis showed a 
statistically significant relationship betvveen RVOT type, PHV recoil upon dilatation. 
RVOT calcification, and stent fracture. 49% of patients who experienced stent fracture 
required reintervention versus 6% who did not have fractured stents. Stent fracture 
grades correlated to restenosis, i.e. fracture ''type I'' was associated with less than or 
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equal to one stent strut failure and had little consequence, but "type II" was associated 
with a loss of stent integrity which would lead to restenosis. Furthermore, the rigid 
platinum-iridium stent and the PA-sternal juxtaposition likely contributed to early stent 
fracture. Additionally, Bonhoeffer et al. reported the first engineering analysis of their 
PHV in 2007. [90] A biomechanical engineering team in Italy performed finite element 
analysis of the Melody stent. Unsurprisingly, they found high stress concentrations at the 
weld locations in the stent. Their model predicted fracture at those locations which 
correlated with in vivo findings. 
4.6. PHV TECHNOLOGY ANALYSIS AND FUTURE GOALS 
All of the aforementioned complications add up to ample opportunity for 
technological investigation and improvement. Biologic valves are known to have short 
useful lives. An alternative material will need to be developed to increase PHV 
durability. Stent deployment, fixation and integrity will have to be improved via rigorous 
study of PHV mechanics. The profile of PHV's will have to be reduced in order to 
accommodate smaller patients and guarantee safe peripheral delivery. Distal aortic 
protection against emboli may need to be developed and PHV retrievability and 
repositionability will be helpful features. More rigorous in vitro and animal testing will 
be required to optimize PHV designs. Effective imaging techniques and a preprocedural 
patient study protocols will need to be developed, which could lead to new imaging uses 
or technologies. [31 ,41 ,4 7,48,50,53, 76,77,78, 79,80,81 ,82.83] 
The physiological and engineering implications of PHV's have only recently 
begun to be investigated. A 2007 study reported results of exercise tests in 17 patients 
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who had received a Melody valve. [57] The results showed that reduced pulmonary 
regurgitation via PHV implantation improved the efficiency of right ventricular ejection, 
left ventricular filling, and increased cardiac output. A 2004 paper published results of an 
investigation into the efTect of Sapien valve implantation on left ventricular function. [84] 
The results shmved kinetic improvement in LV function via Doppler imaging. 
Stock ct al. reported the successful use of tissue-engineering techniques to prevent 
damage to tissue PHV's caused by the delivery process. [56] They seeded acellular 
matrices in pulmonary PHV s and cultured them in a dynamic bioreactor for 16 days. 
Then they crimped and deployed the valves and performed histological studies of the 
tissue. Their results showed that the tissue engineered valves exhibited almost no tissue 
damage whereas the control exhibited extensive cellular damage. This finding could be 
useful in extending the durability of tissue PHV's. 
Attmann et al. investigated the significance of several PHV delivery systems. [34] 
They identified key design requirements for PHV delivery systems including outer 
diameter, inner diameter, and total length versus usable length, flexibility. stiffness. force 
transmission, handling, and durability. They also reported the first histological study of a 
pulmonary PHV. [33] They microscopically examined tissue pulmonary PHV's after 3-
months of service in sheep. Their results showed calcification of the tissue valve 
primarily in the wall. 
PIIV technology has been proven to be feasible by these pioneering researchers 
and inventors, and there is a demonstrated demand for the technology. The future of 
heart. valve prosthetics will likely include PHV's for a while to come. 
38 
The work described herein takes the PHV concept a step further into the future. 
Tissue valves have well known limitations and the ill effects of using tissue valves in 
PHVs have just started to become elucidated. An artificial valve with equal or superior 
hydrodynamics to and superior durability to tissue remains the best choice for PHV s. By 
incorporating state-of-the-art polymers with a functional novel PHV stent design, this 
work will move the technology closer to commercial fruition and possibly lead to a 
breakthrough in polymeric heart valve technology. 
5. PRELIMfNARY PHV WORK AT FlU 
Work on artificial aortic PHV's in the FIU CVEC was initiated by a graduate 
student, named Fernando Jaramillo Arbelaez (FJA), who was awarded a Master's Degree 
in Biomedical Engineering in 2005 for his efforts. [ 69] His aim was to prove the 
feasibility of an artificial aortic PHV. His goals focused on PHV fixation, crimpability, 
leaflet construction, and hydrodynamics. Early on he decided to pursue a Nitinol stent as 
a frame for his PHV design. His initial prototype used a fixation method that was 
intended to clip onto the native leaflet for backflow retention and expand into the left 
ventricle for forward flm:v retention. He also employed a leaflet design that resulted in 
three ellipsoidal cups mounted within a stent, which he called "double coaptation 
leaflets". He reported that preliminary in vitro tests of his leaflet design were comparable 
to the function of a 25 mm diameter bileaflet St. Jude mechanical valve. He also 
endeavored to create a suitable leaflet material by experimenting with different fabrics 
and SIBS coatings. Later he experimented with another leaflet design. which he called 
'·central coaptation leaflets'". It is apparent that his goal was to design leaflets that had 
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the shape of natural leaflets. Furthermore, he created several more stent designs by 
varying the number of tums in the wire and altering the method of fixation. According to 
his conclusions the design he called "MCB", central coaptation leaflets and stent with 
forward and backward flow retention hooks, was his best perfom1ing design. He also 
created a delivery device for the in vitro deployment of his PHV's into a porcine aorta. 
Moreover, he created a device for the mounting of said porcine aorta into the Vivitro 
Systems, Inc. Left Heart Simulator (LHS) for hemodynamic testing of the natural porcine 
aortic valve and his PHV prototypes. His final prototypes were crimpable to less than 24 
F. Ultimately, he created a functional method for manufacturing Nitinol stents and 
proved the concept of an artificial PHV. His work was the starting point for the work 
described herein. 
6. RESEARCH PURPOSE 
The purpose of the research performed here was to move the development of an 
artificial aortic PHV forward through the feasibility stage of development by answering 
the following questions: 
1. What is a superior functional design for an artificial aortic PHV? 
2. What are the appropriate materials for said PHV? 
3. What constitutes a novel functional PHV delivery system design suitable for the 
deployment of the novel PHV design? 
4. Can an artificial aortic PHV produce hydrodynamics comparable to commercially 
available heart valve prosthetics? 
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5. Can the PHV be tested tor deliverability and hydrodynamic parameters vm a 
controlled and repeatable in vitro test method? 
The long term goal is to create an artificial PHV and delivery system suitable for further 
development and movement into animal testing and eventual human testing. 
7. SPECIFIC AIMS AND OBJECTIVES 
The feasibility of the novel PHV m development was demonstrated by 
confonning to the following specific aims: 
1. Quantitative m vitro hydrodynamic characterization of a novel m1ificial aortic 
PHV. 
2. Quantitative in vitro characterization of the PHV' s static mechanical properties. 
3. Quantitative characterization of PHV crimpability. 
4. Quantitative and qualitative comparison of a novel PHV to existing PHV 
empirical data and designs. 
5. Qualitative characterization of a novel PHV delivery system. 
6. Quantitative and qualitative characterization of an in vitro PHV testing model. 
Each of these specific aims provided input into the design of the PHV and its delivery 
system and feedback concerning their performance. Aim 1 indicated the basic feasibility 
of the PHV design via quantifying its in vitro hydrodynamic performance, pressure 
drop across the valve, flow rate, and mean systemic pressure. Aim 2 showed whether or 
not the PHV remained in place under a variety of conditions once deployed into the test 
system, i.e. it exhibited no migration in situ. Aim 3 showed whether or not the PHV 
design could be crimped to a specified diameter for delivery. Aim 4 showed vvhether or 
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not the PHV in development is perfonning comparably to competitor designs and the 
"gold standards''. Aims 1-4 together illustrated the feasibility of a novel PHV. Aim 6 
showed the feasibility of a PHV delivery system. and aim 7 showed the feasibility of an 
in vitro test model. 
The objectives of the research performed as defined by the investigator included 
five major design requirements of aortic PHV's: 
1. Crimpable to 24F or less 
2. Produces a mean pressure drop of 10 mmHg or Jess 
3. Allmvs an average of 5% or less leakage off1ow 
4. Allows no migration in situ 
5. Provides normal physiological pressures and flow rates at a given heart rate, e.g. 
90 mmHg MAP and 5 Llmin CO at an HR of 70 bpm. 
An in vitro test model was developed such that PHV prototype testing could be 
conducted in a uniform, repeatable, and controlled manner. and a catheter could be 
insetied into the LHS during operation for PHV delivery. 
These objectives were justified by the available related clinical and scientific 
evidence. Equation 1 illustrates the direct relationship between the pressure drop across 
the aortic valve and the amount of work done by the heart. An increased work load 
caused by stenosis can cause hypertrophy of the heart and eventual heart failure due to 
decreased compliance in the wall of the heart. Conversely. increased leakage flow 
eventually decreases the amount of work that the heart can perform by decreasing SV, 
which would also lead to cardiac failure by an enlargement and thinning of the heart 
walls causing a decrease in contractility. Additionally, commercially available heart 
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valve prosthetics produce pressure gradients of less than 8 mmHg and leakage flow of 
less than 4%. [3] Furthermore. table 1 shmvs that mild stenosis of the natural aortic valve 
is clinically defined as having a pressure gradient of 25 mmHg or less, and mild 
regurgitation (l+) is defined as having 30% or less leakage flow. [68] Moreover, 
experiments show that having less than 5% regurgitation is necessary for complete valve 
closure during diastole. [1 OJ In general, the maximum dilated diameter of a healthy 
femoral m1ery is 8 mm or 24 F. However. early PHV retrograde delivery reports indicate 
that peripheral vascular disease can compromise this approach. !511 Therefore, using the 
smallest profile delivery catheter possible \vould minimize risks of embolism and 
vascular injury. Finally, a PHV would simply be useless if it could not aid in sustaining a 
proper arterial pressure and cardiac output at a normal heart rate. 
8. METHODS 
8.1. OVERVIEW 
First the project was defined, and then specific aims and goals of the project were 
identified. The work began with the replication of FJA's test methods using the original 
MCB PHV. Critical evaluations of that test experience lead to new insights and 
directions. Concurrently. a thorough literature review was conducted and a new PHV 
concept began to form. PHV prototyping and testing then began, and the design process 
described in the following section was employed. Finally, an objective analysis of the 
verification test data coupled \vith a qualitative analysis of the prototypes, models, and 
methods lead the conclusions reported. 
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8.2. DESIGN PROCESS 
The design process employed for this research followed FDA Regulation 21 CFR 
820.30 Subpart C; Design Controls (figure 1 0). 
User 
Needs 
Validation 
Design A. 
Input. 
Verification 
Design 
Process 
Review. 
" Medical 
Device 
Figure 10: FDA 21 CFR 820.30 Design Control Guidance Diagram. 
In accordance with 820.30 a design history file (DHF) has been maintained, 
which included the laboratory notebooks and all other pertinent documentation generated 
via the design process. Validation testing was not perfonned because a finished product 
ready for transfer to manufacturing has not yet developed. However, verification testing 
was perf{xmed at each stage of the design process. which fed data back into the process 
that aided in improvement of each prototype. 
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8.3. IDENTIFICATION OF NEED 
As presented earlier in this report, there is a clearly demonstrated demand for 
PHV technology by interventional cardiologists and patients seeking less traumatic 
procedures for the treatment of valvular heart disease. This market need has been 
identified via extensive research. 
8.4. RESEARCH 
The history of PHV technology has been extensively researched via academic 
journal database queries, scientific text reviews, clinician interviews, and general internet 
queries. A compilation of the researched information has been utilized to form a solution 
concept. 
8.5. CONCEPT 
A PI-IV concept has been formed based upon the research. The concept draws 
upon known successes and complications concerning currently reported PHV designs. 
Cost and manufacturability intluenced the concept solution as well. 
8.6. DESIGN AND FABRICATION 
8.6. I. THE STENT 
The stent was the frame or support structure for the valve. It also provided for 
exclusion of the diseased native valve and fixation of the PHV in the aortic root. A two 
stacked stent design similar to the first PHV built and tested by Andersen et al., was 
employed because it allowed economical and quick fabrication of prototypes in house. 
The shape of the stent was based upon the Core Valve concept. using an oversized distal 
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stent. and in tum friction, as the primary fixation feature. Fixation of the PHV was 
designed to depend upon over-sizing of the distal stent by at least 20%. Hooks were 
abandoned early on due to their hindrance of delivery and potential to cause trauma to the 
aortic wall. The use of two stents in the proximal portion of the stent where the valve 
resided was chosen after several prototype tests revealed the need for stiffening of that 
section. For the distal fixation stent, tear-drop bends were created at each tum that served 
to stiffen the stent. [59] The added stiffness in each joint reduced the need to have more 
bends in the 'Wire. Therefore, the number of wire bends exposed to the blood was 
minimized because each part of the wire that resides perpendicular to the flow of blood 
tends to induce neointimal hyperplasia and thrombosis. [94] U-shaped bends were placed 
in the proximal stent to facilitate crimping and because the bulk of the surface was 
covered by the leaflet material, and eventually two stents were utilized for added 
stiffness. In contrast to the Andersen valve, our PHV had and over-sized fixation stent 
with geometry that maximized stiffness. and in contrast to the CoreValve design, our 
PHV exposed less stent strut area to the blood and provided larger spaces for the passage 
of catheters into the coronary arteries. 
Initially. the stent was fabricated from commercially available stainless steel wire 
for economy and rapid prototyping. A wooden peg board was used to bend the wire into 
the desired shape as shown in figure I 1. The ends of the wire were joined using stainless 
steel hypodermic tubing and super-glue (figure 12), and the stent was expanded using a 
12 F Bard urinary catheter balloon (5 ml). The initial Nitinol wire stent was fabricated 
using a ceramic peg board and a small butane torch (figure 13). 
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Figure 11: Wooden peg board f!Jr SS wire fom1ing. 
Figure 12: Upper SS wire with hypo-tubing, and lovver urinary catheter balloon used to 
expand the stainless steel stent. 
Figure 13: Bench-top Nitinol wire forming ceramic peg board. (The board is missing 
some dowel pins in this photo.) 
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The Nitinol wire was bent in the pattern of the pegs and the torch \Vas used to 
anneal the wire so that it would retain the desired shape. The process was imperfect and 
produced less than ideal prototype stents. However, the method \vas used for speed and 
economy. 
The final version of the Nitinol stent was manufactured using a method similar to 
Jaramillo's. Steel plates were fabricated \Vith holes drilled in a predetermined pattern, 
and 1/16 inch diameter hardened steel pins were press-fit into the holes (figure 14). A 
top plate was bolted onto the bottom peg-board plate in order to constrain the wire while 
heating. The assembly was heated to 500°C and soaked at that temperature for 5 minutes. 
Then the assembly was removed from the furnace and water quenched. The ends of the 
Nitinol wires were joined in the same manner as the stainless steel wires using stainless 
steel hypodermic tubing (figure 15). The stents produced in this manner were of much 
higher quality than those produced using the butane torch. The diameter of the nitinol 
wire varied with each prototype until an optimal diameter was found via verification 
tests. 
Later, a need for larger diameter stents arose and the annealing plates were 
redesigned (figures 16 and 17). Anchors were incorporated into the new design. 
Figure 14: Steel plate for Nitinol wire annealing in a 500°C furnace. 
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Figure 15: Nitinol wire formed using the steel annealing plates. 
Figure 16: Second generation nitinol wire annealing plate. This allowed for larger 
diameter stents to be manufactured. 
Figure 17: Nitinol ·wire after annealing in the second generation fixture. 
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8.6.2. THE VALVE 
The valve was designed to function as the natural aortic valve, that is, like a 
collapsing tube. An extensive review of human anatomy and physiology was used as a 
primary input to this design. The material used for the valve had been predetermined, but 
material shape and thickness were manipulated during the design process. 
The leaflet material was manufactured using a method created by Siobhain 
Gallacher. A 3x3 inch sheet of Bard Peripheral Vascular P04081 Polyester Fabric Style 
6102 was constrained onto an aluminum drying plate, and 7-8 ml of liquefied SIBS 
(Innovia, LLC.) was poured onto the mesh, and the composite material was allowed to 
cure at room temperature under a fume hood for 48 hours (figure 18). The SIBS polymer 
was provided in the form of small solid pellets and was liquefied by adding toluene 15% 
by mass, i.e. the mixture was 15% SIBS and 85% toluene. [58] Commercially available 
aluminum foil was used as a gasket between the fabric and the drying plate in order to 
provide a space for SIBS to coat the surface of the polyester fabric in contact with the 
mirror finish base of the drying fixture. 
Figure 18: Leaflet composite material and drying plate by Gallacher. One side of the 
leaflet material turns out very smooth (ventricular side-bottom left) and the other is 
rougher (aortic side-bottom right) much like the natural aortic valve. 
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The resulting composite had a thickness between 200 and 250 microns depending 
on the volume of SIBS-toluene mixture added to the polyester fabric. Once the SIBS had 
cured, the composite sheet was removed from the plate and cut to the desired valve 
dimensions. 
The test conduit diameter \Vas 19 mm, so the leaflet material was cut to form a 
cylinder of equal diameter. The length (L) of the leaflet material was ideally L=J[d:::::60 
mm. where d was the conduit diameter. The height (H) of the cylinder (valve) was 
calculated using the formula H=r(l.245):::::12 mm. where r was the radius of the conduit. 
The resulting H value was considered ideaL The constant 1.245 was the mean value of 
the H multipliers extracted fi·om anatomical studies cited in Thubrikar 1990. i.e. if r=1, 
then H=1.245. [ 1 0] The height of the stent (h) was approximately h=2H:::::24 mm. A 19 
mm diameter was chosen for the PHV prototype. because it matched the diameter of the 
amiic root of a small adult human and a sheep. which was the preferred test animal due to 
its blood coagulation characteristics and slow grm:vth. A purse-string style stitch was 
used to join the overlapping ends of the fabric in order to form a cylinder (figure 19). 
Figure 19: Dacron-SIBS composite leaflet material. Cylindrical form used for valve 
formation shown on top of a flat composite sheet. Scale is in centimeters. Notice the 
purse-string suture pattern used to form a cylinder. 
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8.6.3. THE PHV 
A detailed protocol of PHV construction is located in the appendix. The valve 
material was sutured to the stent via braided polyester suture (Ethibond Excel 4-0). This 
suture was chosen because it has a high tensile strength, it resists breaking when flexed or 
knotted, and it is being used in the manufacture of commercially available abdominal 
aortic aneurysm (AAA) stent grafts. In lieu of welding, the suture was utilized to join 
segments of the stents as needed (figure 20). The final step in the process was the 
placement of one stainless steel ball bearing behind each of the three leaf1ets, and the 
placement of the PHV onto the 19 mm diameter mold spacer. This was performed in 
order to anneal the leaflets into the hemispherical shape of natural leaflets (figure 21 ). 
The assembly was placed inside a 60°C oven for about 2 hours for shape setting. 
Figure 20: PHV shown during assembly. 
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Figure 21: PHV in place on the 19 mm diameter SA mold spacer with SS ball bearings 
ready to be placed into the oven for annealing. 
8.6.4. THE DELIVERY SYSTEM 
It \vas determined via literature review that the PHV should be delivered 
retrogradely to the heart via peripheral arterial access. So a mechanism capable of doing 
so had to be designed. Ideally, a commercially available vascular catheter would have 
been be utilized. but there are very few available for delivering such large diameter 
devices. Therefore. a device had to be designed that could accommodate the PHV and at 
the same time fit into the lumen of an average large peripheral artery, e.g. the internal 
iliac artery. Additionally. a feature was added to the design that would enable "steering" 
of the catheter in situ so that the catheter could be centered in the aortic lumen prior to 
valve deployment. Finally, a mechanism was designed such that the retraction of the 
catheter sheath could be controlled with respect to the retraction distance. The catheter 
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hand piece (Figure 22) was designed in SolidWorks SP3.1 2005 and machined from 6020 
Aluminum. Catheter style FEP tubing was donated by Zeus Industrial Products, Inc. that 
had an 0 D of 24 F and an ID of 7 mm and a length of 1 m. Internal support wires for the 
catheter were composed of Nitinol with 0.040 inch and 0.050 inch diameters were 
purchased from Small Parts, Inc. A Boston Scientific Jagwire 0.035 inch was used as a 
guide wire (figure 25). The catheter tip (figure 23) and stopper (figure 24) were designed 
in SolidWorks SP3.1 2005 and machined from white Delrin. The tip was designed with 
two lumens. One was drilled through at an offset angle with respect to the tip for passage 
of a guide wire and the other terminated inside the tip for anchoring of the internal 
support wire. The stopper was designed to fit tightly onto the Nitinol support wire so 
that the PHV could be crimped and inserted into the catheter between the tip and the 
stopper. The stopper functioned to hold the PHV in place while the sheath was retracted 
during deployment. It also was designed for attachment of the steering line and fixation 
of the central stopper wire. The steering mechanism employed a braided fishing line 
called Spectra@ by Power Pro of 15 lb test. The hand piece was assembled as shown in 
figure 22. The Jagvvire passed through the guidewire slot on the top of the hand piece 
and on through the catheter tip, and the two internal nitinol wires were held in place via 
the set screw in the catheter hand piece. The spool was attached to the most distal portion 
of the catheter via Elmer's Krazy glue. (Ideally, the catheter and spool would be a single 
molded piece.) The fishing line was attached to the catheter stopper and threaded 
through the catheter lumen and into the steering rod of the hand piece. 
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Figure 22: Deployment device hand piece. On the left, the Jagwire is shown protruding 
from the guide wire slot and the fishing line used to steer the catheter is shown hanging 
from the ring of the steering rod in the hand piece. On the right, the hand piece is shown 
fully disassembled. 
Figure 23: Catheter tip. 
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Figure 24: Stopper. 
Figure 25: Zeus 24 F catheter tube with catheter tip and Jagwire. 
8.6.5. THE PHV CRIMPING TOOL 
It became apparent through the course of this work that crimping the PHV by 
hand for insertion into the delivery catheter was quite challenging. Therefore, a tool for 
doing just that was designed (figure 26). It was designed so that the PHV could be 
uniformly and cylindrically crimped to its smallest possible diameter or a diameter less 
than or equal to 7 mm, which was the ID of the catheter sheath. Additionally, it was 
designed to hold the PHV in the crimped conformation once it was achieved. Finally, it 
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was designed to allow crimping of the PHV over the internal support wire of the catheter 
and insertion of the PHV into the catheter sheath (figure 27). 
Figure 26: PHV crimping tool. 
Figure 27: The PHV crimping tool shown with PHV inside the PTFE loop over the 
deployment catheter. 
The crimping tool was machined from Delrin, aluminum and brass. The base 
block was Delrin, and spool shaft was brass and the spool knob was aluminum. These 
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materials were chosen for ease of machining and economy. A 0.015 inch thick PTFE 
sheet was attached to the Delrin block and to the brass spool shaft and was used to crimp 
the PIIV by winding the sheet around the shaft of the spool. As the spool was wound the 
loop of PTFE sheet on the opposite side of the block containing the PHV would squeeze 
the PHV into a smaller diameter conformation (figure 28). A ratchet-spring mechanism 
was designed to hold the spool at the desired level of tension. 
Figure 28: PHV crimping tool shown during the crimping process. 
8.6.6. THE FRENCH SIZER 
A French scale sizing block was designed using SolidWorks and machined from 
Delrin for the purpose of testing the crimpability of each prototype PHV (figure 29). It 
contained holes varying in size from 24 F-12 F. Each hole had a chamfered opening to 
facilitate crimping and insertion. The depth of the holes was designed to be greater than 
the maximum length of the PHV so that complete crimp testing of the PHV prototype 
could be performed. A commercially available equivalent tool could not be found. 
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Figure 29: French scale block machined from Delrin. 
8.6.7. THE MODEL AORTA 
The Vivitro LHS in the CVEC was not designed and built for PHV testing. so the 
design of modifications to the system was essential to this work. It was determined 
during replication of the FJA experiments that the use of animal aortas inside the LHS 
introduced unnecessary complications to the project. Therefore, it was decided that a 
more consistent and less labor intensive method of testing the PHV prototypes in the LHS 
would be designed. It seemed a logical choice to create a silicone tube or aorta (SA) that 
could replicate the function of a real aorta without the variability and the labor intensity 
of the latter. The SA was designed to bypass and exclude the LHS characteristic (aortic) 
compliance chamber because in the end it was designed to be sufficiently compliant so as 
to replicate the built-in aortic compliance effects on the dynamics of the system. The 
internal diameter of the SA \Vas designed to be 19 mm. The tube was also designed to be 
transparent, which facilitated visualization of PHV perforn1ance during normal operation. 
The silicone rubber used was Sylgard 184 silicone elastomer by Dow Corning. It was 
initially mixed in a 10:1 ratio v.ith the curing agent as specified by the manufacturer. The 
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mixture was placed in a vacuum chamber to remove all air prior to pouring into the mold. 
Once poured into the mold, a central pin was inserted into the mold to create the 19 mm 
inner diameter. The silicone was allowed cure at room temperature for 48 hours. 
Initially, a mold was designed to retrofit the FJA animal aorta apparatus with a 
silicone tube. The first generation silicone mold (figure 30) was machined from 304 
stainless steel and PTFE shrink tubing was employed. The process for making and 
curing the first generation SA was imperfect, as illustrated by the tube shown in figure 
30. The silicone contained many air bubbles and the wall thickness was not unifonn. 
This prompted a return to the proverbial drawing board. 
Figure 30: Silicone Aorta first generation mold with shrink tubing and SA 1.0 with FJA-
MCB by Claiborne deployed inside. Initially, the FJA mounting apparatus was 
employed. 
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The second generation SA mold was designed to eliminate the need for the FJA 
mounting apparatus and to produce consistently uniform and air bubble free silicone 
aortas. It was designed as clam shell using Solid Works and \vas machined from 6020 
aluminum (figure 31 ). 
Figure 31: Second generation silicone aorta (SA 2.0) and clam-shell mold. 
Initially, compliance of the SA was ignored. The concern instead was structural 
rigidity such that the SA would form a water tight seal and bypass the compliance 
chamber during rigorous operation of the LHS. When the proof of concept had been 
established, compliance was designed into the SA molding process. To that end, spacers 
were designed for insertion into the mold. This allowed variation of the wall thickness of 
the SA (figure 32). Moreover, compliance was manipulated by altering the ratio of 
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curing agent to elastomer. A larger ratio, i.e. less curing agent, resulted in a more elastic 
silicone rubber product. 
Figure 32: The silicone aorta clam-shell mold with spacer insert for wall thickness 
modification is shown with SA 2.1 (top left), SA series style 2.2 (bottom left), and SA 2.5 
(bottom right). SA 2.5 was wrapped with polyester fabric in order to limit the amount of 
stretch during testing inside the LHS. 
8.7. VERIFICATION TESTING 
8.7.1. IN VITRO MODEL 
In vitro model verification was performed via Matlab Simulink modeling of a 
two-element Windkessel model (figure 34). The model used an iterative nonlinear least 
squares method fit a curve to the pressure waveform data recorded during testing and to 
calculate the systemic resistance and compliance values for each test run. A good curve 
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fit to the data indicated that the Windkessel model was accurately predicting the systemic 
resistance and compliance values (figure 33 ). A normal distribution of the residuals 
centered around zero \vas an indicator of the goodness of fit 
Figure 33: A sample of the Matlab Windkessel nonlinear least squares curve fit to the 
aortic pressure wavefom1 data collected during a PHV LHS test. 
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Figure 34: The Matlab Simulink two-element Windkessel model used to numerically 
solve the differential equation and calculate the coefTicients Rand C. 
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8.7.2. FIXATION 
PHV fixation testing was performed using a method similar to that described in a 
2007 paper by Zhou et al., wherein they tested the displacement force of aortic stent 
grafts by deploying the grafts into animal aortic segments and pulling the grafts axially. 
Their results showed initial displacement forces between 3 and 33 N depending on the 
type of graft and the magnitude of over-sizing (5-20%). [63] Our tests were conducted by 
anchoring SA 2.1 to the mobile top anchor ofthe Bose ELF 3200 via #1 Ethibond suture 
and tethering the PIIV. deployed inside the SA. to the bottom fixed anchor of the system 
(figure 35). The suture attached to the PHV was separated and held parallel to the wall of 
the tube via an aluminum disc so that no bending moments would be applied to the PHV 
during the test. It was believed that a bending moment applied to the tethered end of the 
PI-IV could have caused it to prematurely loosen and slip. The Bose system was set for 6 
mm of displacement, but the value of interest was the force required to cause slippage of 
the PJ-IV. Therefore, the displacement was not considered critical, i.e. the SA exhibited 
some elastic deformation prior to PHV slippage during the tests, but this was ignored in 
terms of potentially confounding variables. It was assumed that the natural aorta would 
also exhibit clastic deformation both the axial and radial directions in vivo during the 
cardiac cycle. Moreover, the SA and the PI-IV were both wetted with the blood analog 
solution used in the LHS. This was done in order to reduce surface contact friction 
between the PHV and the inner surface of the SA and to improve the realism of the test. 
The force required to make the PHV slip was called the fixation force. 
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Figure 35: Fixation force testing apparatus. Sapien PHV shown inside wetted silicone 
aorta 2.1 suspended with #1 Ethibond sutures. Notice the aluminum disc at the base of 
the apparatus separating the three sutures tethered to the PHV. 
8.7.3. COMPRESSION 
Each PHV prototype was placed inside a custom made apparatus m order to 
measure radial compression and axial slippage forces (figures 36 and 37). The radial 
compression tests were perfonned using a Teflon sheet that was cut into a shape that 
would allow the Bose ELF 3200 to convert linear motion into rotational motion, i.e. as 
the machine increased the linear distance between its two anchors; the Teflon sheet loop 
would decrease in diameter. Therefore, the force measured was taken to be the hoop 
force of the PHV. The hoop force was converted to radial force using the relationship 
shown in equation 32. 
Equation 32: Radial Force: Fr=Fo2rr 
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Teflon was chosen so that the PHV would be able slip with minimal friction as the 
diameter of the loop decreased. The thickness (0.015 inch) of the Teflon sheet was 
chosen qualitatively by testing the balance between tear resistance and stiffness. The 
starting diameter of the Teflon sheet loop was set to 21 mm at the beginning of each test 
using a stainless steel cylinder of the same diameter. The maximum linear displacement 
of the Bose ELF 3200, 12 mm, was executed during each test. The result was an 18% 
decrease in diameter for each test. By comparison normal pulse pressure diameter 
change of the aortic root in a young healthy adult human is in the vicinity of 10%. 
Figure 36: PHV compression testing set-up. A Teflon sheet was used to compress each 
PHV. The starting diameter of the compression test was set to 21 mm by using a 
stainless steel cylinder with a diameter of 21 mm. 
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Figure 37: PHV shown inside the compression testing apparatus. Linear force was 
converted to hoop force. The measured force was taken to be the hoop force for each 
PHV. 
8.7.4. HYDRODYNAMICS 
Hydrodynamic tests have been performed usmg the Vivitro Systems, Inc. 
Superdup'r Left Heart Simulator (figure 38). Twelve test runs per prototype were 
attempted during each test. Of the twelve total runs. three runs each were performed at 
45, 70, 100, and 120 bpm, at target mean flow rates of 2.3 to 11.4 L/min respectively in 
accordance with the FlU Hydrodynamics Testing Protocol written by Siobhain Gallocher 
and included in the appendix. LHS test measurements \Vere recorded using a PC running 
AcqKnowledge 3.2.3 software acquiring data from a Biopac Systems, Inc. MPlOOA 
connected to two Millar Instmments Mikro-Tip Catheter pressure transducers inserted 
into the LHS ventricle and aorta respectively. and a Carolina Medical Square-Wave 
Electromagnetic Flow Sensor positioned at the based of the aortic outflow tract in the 
LHS. 
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Figure 38: Vivitro Systems, Inc. Superdup'r Left Heart Simulator. 
The heart rate was set using a Vivitro Systems, Inc. Tri-Pack TP 2001 Square 
Wave Generator. The flow was generated using a Vivitro Systems, Inc. Superpump 
SP A3 891 Servo Power Amplifier connected to a Superpump Piston-in-Cylinder System. 
A blood analog solution composed of 35% glycerin and 65% deionized water by volume 
with 9 grams of sodium chloride per liter was used during LHS testing. The resulting 
solution had a density of 1.133 g/ml and a viscosity of 3.2 cP, which was similar to whole 
blood. Characteristic waveforms produced by the system are shown in chart 1. 
A mock aortic How loop was designed to redirect flow through the LHS into the 
loop so that dynamic delivery and deployment testing of the PHV could be perfom1ed, 
i.e. the LHS was operating and the delivery catheter was threaded into the LHS and 
positioned for deployment of the PHV into the SA inside the LHS. 
The compliance of the silicone aorta designed for PHV testing inside the LHS 
was measured on the bench-top using a Labtron Accumax Blood Pressure Cuff and a 
Standby Baumanometer (figure 39). Diameter and pressure changes were measured 
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usmg digital calipers with 0.01 mm accuracy and compliance was calculated usmg 
equation 6. Three measurements of the diameter of the SA were taken at a set pressure 
and then the average of those values was used to calculate compliance. 
Characteristic Waveforms Generated by the Vivitro LHS Sytern 
I 
I 
l 
I 
Time(s) 
!, 
!· 
I· 
I; 
1: 
I, 
1: 
I; 
I 
I 
I 
I 
I 
l 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
J: 
I' 
I, 
!· 1: 
t: 
I' 
I; 
25 
20 
15 
-e 
·e 
2 
10 s 
I 1<1 
! 0:: 
\ ~ I 
I u. 
I 5 
I 
I 
I 
I 
I 0 
-5 
Chart 1: Waveforms generated by the Vivitro LHS \Vith its original settings and a 25 mm 
St. Jude bileaflet mechanical valve in the aortic position. 
Figure 39: Silicone aorta compliance testing apparatus. 
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Figure 40: LHS with mock aortic flow loop for dynamic PHV delivery and deployment 
testing. 
8.7.5. DELIVERY SYSTEM 
Lutter et aL published a paper in 2006 detailing the in vitro testing of a few 
different PHV delivery systems. [34] For in vitro testing, they constmctcd a silicone 
model of the heart and the venous vascular system to simulate antegrade deployment. 
They measured the devices' physical characteristics. e.g. ID, OD, total length, and usable 
length, and they created a qualitative scoring method for grading the devices' flexibility 
or ductility, stiffness, transmission force, handling, and durability. They also measured 
the device placement time, the stent deployment time, the device retrieval time, the 
number of tests producing material fatigue, the radius of curvature, and the radial force. 
Similarly, our delivery system was tested on the bench-top via deployment of the PHV 
into a one inch diameter polycarbonate tube shaped like an aorta simulating retrograde 
deployment (figure 41 ). The test was perfonned by inserting the catheter into the "aorta", 
retracting the sheath, deploying the PHV and removal of the delivery catheter from the 
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tube. Deflection of the catheter tip was tested by manipulating the steering rod in the 
hand piece (figure 42). However, the rigorous test methods employed by Lutter et al. 
were not duplicated. Instead. a purely qualitative assessment of the system was 
perfonned. aside from the physical dimensions being recorded. due to time and budget 
constraints. i.e. the catheter tubing was not ideal for such rigorous testing. 
Figure 41: Polycarbonate tube used to test PHV delivery system. A silicone aorta was 
attached to the end as a receptacle for the PHV. 
Figure 42: Delivery system hand piece. Guide \vire is shown protruding from the slot. 
The steering wire is shown attached to the ring. 
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8.8. DATA ANALYSIS AND STATISTICAL METHODS 
The data set from each LHS test has been processed via a custom Matlab 6 
program designed to calculate the aforementioned hemodynamic parameters, which is 
included in the appendix. The resulting data was statistically analyzed using SPSS 13.0 
software. One-way ANOVA and Tukey's post hoc tests were performed for each 
parameter of interest in order to compare the difference between means of each 
prototype. 
9. RESULTS 
9.1. BASELINE: ST.JUDE VALVE 
The LHS was designed for the testing of surgically implanted heart valves. 
Therefore, a baseline test of the LHS v .. -ith a 25 mm diameter St. Jude bileaflet 
mechanical valve was performed for comparison to PHV performance. These results 
\Vere considered the "gold standard" for which the PHV development in this research was 
striving. The tests showed a mean valvular pressure gradient of 4.3163 mmHg and a 
mean regurgitation of5.7851%. 
9.2. FJA-MCB 
9.2.1. ORIGINAL 
Work began with the replication ofthe FJA hydrodynamic tests of his MCB PHV 
(figure 43). The valve was clearly worse for the \vear at the time of the test. It is shown 
partially disassembled as a result of later investigations into construction methods. 
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Figure 43: Original FJA-MCB prototype. Wear and tear is evident. Notice the relaxed 
triangular shape. 
This work began by obtaining porcme hearts from a local slaughter house 
(Cabrera's). The aortic root was dissected from the heart while leaving the native aortic 
valve intact. SIBS-polyester composite sheets were sutured to each end of the vessel 
using silk suture as shown in figure 44. The vessel was mounted onto the FJA porcine 
aorta fixture shown in figure 45. The assembly was placed inside the LHS as shown in 
figure 46. 
Figure 44: Photo trom FJA Thesis showing polymer coated polyester sheet attachment to 
a dissected porcine aortic root. 
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Figure 45: FJA porcine aorta fixture and MCB valve shown with various sized outlets. 
Figure 46: Porcine aorta inside the LHS during testing. 
Initially, the porcme aortic segment and natural valve were tested alone. 
Physiological flow rates and pressures could not be achieved due to observed collapse of 
the aorta during systole and apparent looseness of the vessel attachment to the FJA 
fixture. Therefore, no data were recorded. 
Later. the vessel was adjusted for fit, tension, and leakage. The FJA-MCB valve 
was then inserted into the native porcine valve, and the assembly was placed inside the 
LHS for a second test. Again, the data from the experiment was not recorded because 
physiologic flow could not be achieved, i.e. MAP=90 mmHg and C0=5 Llmin. As 
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before, vessel collapse during systole and flow leakage at attachment sites was observed. 
The collapsing of the vessel distorted ventricular pressure readings by causing the 
pressure to spike to maximum at each cardiac cycle. Another attempt was made to 
tighten the fit of the aortic root, but improvement in the hemodynamics was minimal. 
The test was repeated using other porcine aortic roots, but the same results were obtained. 
Furthermore, accurate deployment of the FJA-MCB valve was hampered by difficult 
visualization and hook impingement on the inner surface of the delivery sheath. The 
PHV itself exhibited very little movement and therefore was insufficient. In all tests the 
maximum porcine aorta diameter obtained was 17 mm. The FJA-MCB valve was 
designed for a 19 mm vessel. It was determined that the use of a porcine aorta for PHV 
testing was laborious and difficult to control, and therefore would result in inconsistent 
test conditions and bias the test results. 
The experience lead to the realization that at the FJA-MCB valve had to be rebuilt 
due to the degraded condition of the tested valve. Additionally, the decision was made to 
design an alternative test conduit to replace the porcine aorta. 
9.2.2. REBUILD 
The results obtained from the test of the original FJA-MCB valve prompted the 
fabrication of a new FJA-MCB valve prototype for testing. The process of doing so 
facilitated learning of the FJA PHV manufacturing method. A new FJA-MCB valve was 
constructed based upon inforn1ation in the FJA thesis and physical inspection of the 
original FJA-MCB valve in possession. A detailed description of the FJA-MCB PHV 
construction was written by the author and is included in the appendix. The original FJA 
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Nitinol annealing plates were used to shape the 0.019 inch diameter Nitinol wire into the 
proper shape. The shaping process required two heating cycles; the first step set the 
primary wire turns and the second step set the bends that would become the hooks. Some 
improvisation was required in the process due to missing components of the FJA 
assembly system. The initial wire bending pattern was found by iteratively bending 
copper wire in various shapes, as shown in figure 47. 
Figure 47: Process of detern1ining wire forming pattern for FJA-MCB using the FJA 
annealing plates and copper wire. 
Each stent segment was joined using 0.040 inch ID thin-walled stainless steel 
hypo-tubing. However, FJA specified the use of 0.032 inch ID hypo tubing, but after 
several unsuccessful attempts to pass two 0.019 inch (0=0.038 inch) wire ends through a 
segment of the tubing it was abandoned for the larger tubing. The leaflet material was 
fabricated using the FJA polyester fabric remaining in the CVEC and the SIBS polymer. 
The result was a material with a thickness of about 250 microns. The leaflet material was 
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cut according to the FJA method for creating "central coaptation" leaflets. [69] The three 
leaflets were joined and mounted onto the stent using Ethibond sutures. The resulting 
FJA-MCB PHV is shown in figure 48. 
Figure 48: New FJA-MCB valve by Claiborne. Notice the characteristic relaxed 
triangular shape. 
The new FJA-MCB valve was mounted inside the first generation silicone tube 
(SA 1.0) and dilated using a Bard 12 F urinary catheter with a 5 ml balloon as shown in 
figure 49. The urinary catheter balloon was latex and therefore could not exert high 
radial forces akin to polyurethane vascular balloon catheters, but it was sufficient for this 
experiment. Its purpose was dilatation of the PHV and embedment of the flow retention 
hooks into the silicone aorta wall. As with the former FJA-MCB physiological values 
could not be obtained, but the valve perforn1ed well enough to record some data. 
However, the valve showed proper trends in perfonnance as shown in charts 2 and 3. 
The valve was tested at 70 bpm for nine runs. The mean cardiac output was 5 Llmin, the 
mean arterial pressure was 34.5 mmHg, the mean pressure drop across the valve was 12.4 
mmHg, and the mean regurgitation was 41%. 
77 
Figure 49: SA 1.0 mounted onto the FJA porcine aorta fixture with new FJA-MCB in 
situ. A urinary catheter balloon was used to open and fix the PHV inside the SA. 
A mean regurgitation of 50% would be expected if there were no valve in the test 
conduit. This can be explained by the observations that the valve did not have a good fit 
inside the SA (figure 50), i.e. it appeared to be somewhat oversized as evidenced by the 
buckling and overlap of the leaflets in the unload conformation. Moreover. the outer 
edges of the valve did not lay flush with the wall of the tube even after balloon dilatation. 
The hooks were observed to be protruding through the tube wall, but some shifting of the 
valve occurred during testing. 
Figure 50: New FJA-MCB valve inside the first generation 19 mm diameter silicone 
aorta. Notice the leaflets appear to be oversized. The view is looking proximally toward 
the ventricle. 
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Chart 2: New FJA-MCB valve test in first generation silicone aorta. The trend of 
regurgitation as a function of cardiac output data shown here is as it should be for a heart 
valve, but the slope is too steep and the values show a wide variation in distribution. 
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Chart 3: New FJA-MCB valve tested in the first generation silicone aorta. The trend in 
mean forward flow pressure drop as a function of mean forward flow rate is as it should 
be for a heart valve but again the slope is too steep. However the grouping of data points 
shows a good fit to the trend line. 
9.2.3. RETEST: SA 2.0 
It was hypothesized that a portion of the poor performance of the new FJA-MCB 
valve could be attributed to the poor design of SA 1.0. Therefore, the SA mold was 
redesigned. The new mold design and resulting SA eliminated the need for the FJA 
porcine aorta fixture and improved the manufacturability and quality of the silicone 
aortas. The SA 2.0 was used to retest the new FJA valve and the FlU-Hydrodynamics 
testing protocol written by graduate student Siobhain Gallocher was followed. This test 
exposed the valve to much higher t1ow rates than the initial test with the first generation 
silicone aorta. During this test the pressure drop across SA 2.0 without a PHV was 
80 
measured. The introduction of smaller diameter flow conduit to the LHS produced an 
intrinsic pressure gradient. This gradient \Vas assumed to be additive to the PHV induced 
gradient and was thcrei()re subtracted from all raw PHV pressure drop data points to 
arrive at an ''adjusted'' value. This value was called the "tube factor" ( 4.65 mmHg for SA 
2.0). Results produced a mean adjusted mean pressure gradient of 37 mmHg and a mean 
regurgitation of 15.4%, v>ith a mean cardiac output of 6 L/min and a mean pressure of 
about 50 mmHg. These results were a slight improvement overall, but a large 
improvement in tenns of regurgitation, with a 62% improvement. So the fit and 
sufficiency of the valve improved with the new silicone aorta. 
9.2.4. FJA VALVE SUMMARY 
Once replication of the F JA-MCB PHV valve and tests were complete and the 
data had been analyzed, an objective assessment of the valve and test methods was 
executed. The vveakness noted in the F JA-M CB PHV design and testing process were ( 1) 
a lack of radial force in the stent design, which effectively negated the intended self-
expanding characteristics of Nitinol, (2) poor leaflet function in tem1s of insufficiency 
and pressure gradient (3) the use of hooks for fixation added to the difliculty of 
deployment of the PHV by impinging on the delivery device inner surface, ( 4) the design 
was overly complicated in terms of requiring many pieces and steps to be manufactured, 
(5) the method of using a porcine aorta for PHV LHS tests introduced variability, 
increased labor, and produced unreliable results, (6) the FJA test results could not be 
replicated. The strengths noted were the robust stent annealing and shaping process and 
the elimination of potential designs for a PHV and testing methods. For these reasons the 
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FJA-MCB design and primary test methods were abandoned. The next phase was to use 
this information to start designing a novel PHV and to refine the testing process. 
9.3. NOVEL PHV PROTOTYPING 
9.3.1. TC PHV 0 
The first conceived prototype was a simple design that was intended to test 
manufacturability of PHV' s in the lab and to flesh out an initial concept (figure 51). The 
valve was not hydrodynamically tested. 
Figure 51: TC PHV 0 concept. 
9.3.2. TC PHV 1 
Design of the TC PHV 1 prototype was based upon all the pnor research 
perfom1ed (figure 52). The initial goal was to create a design that could survive LHS 
testing. For rapid prototyping and to keep costs down. 0.019 inch OD 304 stainless steel 
wire and the FJA polyester fabric-SIBS composite were utilized. The stent was a simple 
Z-stent shape with added tear-drop bends that were designed to increased stiffness in 
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each tum of the wire. The SIBS-polyester composite leaflet material \Vas formed into a 
cylinder that was attached to the stent distally at three equally spaced intervals. The 
valve design was a collapsing cylinder which was meant to mimic the construction and 
movement of a natural aortic valve. Two stents were fom1ed and joined together at the 
ends using 0.040 inch ID, thin-,valled. 304 stainless steel hypodem1ic-tubing. Each half 
of the stent and the leaflet material was joined using 4-0 Ethibond Excel polyester suture. 
Figure 52: TC PHV 1. The upper bare stent \Vas intended for fixation. 
The LHS test of TC PHV 1 was conducted using SA 2.0 and ended abn1ptly with 
catastrophic failure of the valve (figure 53). The valve completely prolapsed and the 
stents dehisced at the sutures. Table 2 shows the data recorded prior to failure. The 
initial data indicated the presence of a high pressure drop and a large amount of 
regurgitation. 
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Figure 53: TC PHV 1 after LHS test. The two stents separated and the valve completely 
prolapsed. 
Positive Positive Cardiac Stroke Mean Leakage Mean t.P 
Scenario HR MAP Mean t.P Max Output Volume Forward Flow during Regurgitation % (bpm) (mmHg) Pressure Flow Rate Volume forward flow (mmHg) (mmHg) (Umin) (mL) (Limin) (mL) (mmHg) 
TC PHV 1 70 60 3477 34 1781 116.0407 2.1414 68 0183 11.7659 37 4581 29.7066 55.0706 
Table 2 TC PHV 1 test data p rior to valve failure. 
9.3.3. TC PHV 2 
The results from TC PHV 1 indicated that the design needed to be much more 
robust. TC PHV 2 saw the addition of three axial support struts and more sutures all 
around using the same 0.019 inch SS wire (figure 54). 
Figure 54: TC PHV 2. Notice the vertical struts and reinforcing sutures. 
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The valve was an improvement over TC PHV 1. The adjusted mean pressure 
drop vvas 31 mmHg and the mean regurgitation was 21% as tested in SA 2.0. As 
intended the design changes strengthened the PHV and it did not have any structural 
failures. However, the axial support struts were in the t1ow stream and may have 
impeded t1ow. Moreover, it was difficult to manufacture and secure the struts for testing. 
Therefore, the design of free component struts vvas abandoned. However, it was noted 
that some sort of axial stitTness would be required for future designs. Such a feature 
would prevent sections of the PHV from moving relative to one another. This would be a 
useful characteristic in deployment of the PHV and presumably in its in vivo operation. 
9.3.4. TC PHV 3 
The next iteration of PHV was completely different. The intent was to fabricate a 
nitinol frame PHV that did not require annealing for shape fonning and one which 
aggressively addressed regurgitation and perivalvular leakage. The resulting "out-of-the-
box" PHV is shown in figure 55. 
Figure 55: TC PHV 3 with 0.020" OD SEN wire at the annulus and 0.015" OD SEN wire 
supporting the leaflets. 
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During the initial test using SA 2.0 some migration was observed, so a stainless 
steel fixation stent was attached to TC PHV 3 and the LHS test was continued (figure 
56). The valve performed well in tem1s of pressure drop, with an adjusted mean value of 
23 mmHg, but the design had the opposite effect on regurgitation. with a mean value of 
26%. Due to time and cost constraints, it was determined that the design of TC PHV 1 
was the path that would be developed during this research. 
Figure 56: TC PHV 3 with 0.015" 00 SS wire stent. 
9.3.5. TC PHV 4.0 
With TC PHV 4.0, a return the design concept of TC PHV 1 was made. 
However, the vertical struts of TC PHV 2 were abandoned due to the increase in flow 
obstruction and mass caused by the bars, i.e. they hampered crimpability and flow. 
Ideally they would remain in order to provide axial stiffness to the stent, but 
manufacturing limitations prevented the proper mounting of struts. Moreover, the use of 
Nitinol in prototyping began. An initial prototype was fabricated using 0.019 inch 
diameter nitinol wire with a new peg board composed of ceramic with 1116 inch steel 
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dowel pins. Ceramic was chosen so that a butane torch could be used to anneal the 
Nitinol wire on the bench top in order to facilitate rapid prototyping. The results were 
crude but workable (figure 57). Additionally, a design change in the leaflet attachment 
was made in order to address leakage flo\v. A cylindrical cuff of leaflet material was 
attached to the outside of the proximal stent frame. The outer cuti and inner cuff were 
sutured together at the based of the PHV using a running loop-stitch. The design was 
intended to form a seal between the wall of the SA and the stent. 
Figure 57: TC PHV 4.0 made with 0.019" OD SEN. 
The test results using SA 2.0 showed that the valve was an improvement over TC 
PHV 2, with an adjusted mean pressure drop of 25 mmHg and a mean regurgitation of 
13.5%, which translated to a 19% decrease in pressure drop and a 36% decrease in 
regurgitation compared to TC PHV 2. Crimp testing showed that TC PHV 4 could not fit 
into the 24 F slot. 
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9.3.6. TC PHV 4.1 
The favorable results from TC PHV 4 indicated that the PHV design was on track. 
The next steps were to address pressure drop and crimpability. Concurrently, a thinner 
walled silicone aorta was designed by adding a modification to SA mold 2.0. The 
resulting silicone aorta was called SA 2.1 and was used to test TC PHV 4.1 in the LHS. 
Moreover, the SIBS-Dacron composite leaflet material was used in TC PHV 4.1 instead 
of the clothing grade polyester fabric. Furthermore, a new peg board was designed for 
furnace annealing of the nitinol wire. This f~lbrication method change allowed a 
standardization of the manufacturing process and produced higher quality parts. TC PHV 
4.1 was then constructed using 0.015 inch OD SEN wire (figure 58). Another addition to 
the manufacturing process was made with this prototype; three 5/16 inch SS ball bearings 
and an oven set between 60-70°C were used to plastically shape the leaflets. Finally, a 
loose cuff was added to the outside of the base of the stent to reduce regurgitation and 
encourage leaflet closure in a manner similar to the sinuses of Valsalva. 
Figure 58: TC PHV 4.1 and leaflet shaping technique. 
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The result was an elegant valve that could not hold position during testing. The 
small diameter wire was too weak to resist the diastolic load and the valve migrated into 
the ventricle during testing. Therefore, crimpability was moot for this prototype. Only 
three data sets collected at 45 bpm were recorded before failure (Table 3). The adjusted 
mean pressure drop was 6 mmHg and the mean regurgitation was 5%. 
Pos~ive Mean leakage Mean liP Adjusted Mean Target Positive Max Cardiac Stroke Forward Flow during Regurgitati liP during Prototype HR(bpm) co Mean AP Pressure Output Volume Flow Rate Volume forward on°/o forward flow (Litnin) (mmHg) (Umin) (mL) flow (mmHg) (Umin) (mL) tmmHol (mmHg) 
TCPHV4.1 45 23 20 5930 38 5404 2 2720 E6 6356 86:034 3 1310 13 5410 66100 49260 
45 36 26 0588 52 7613 3 5692 &~ 0231 11 5358 5 1349 20 0082 60394 11 3932 
45 50 14 1175 56 4091 5 0712 115 9749 66809 3 3525 101960 2 8907 1 5810 
mean 45 3.6 20.2574 49.2369 3.6375 85.8445 8.9567 4.0748 14.5817 5.1800 5.9667 
TC PHV 4,1 MIGRATION AT 70 bpm 
Table 3: Data collected for TC PHV 4.1 prior to valve migration into the ventricle. 
9.3.7. TC PHV 4.2 
The lesson leamed in TC PHV 4.1 was applied in TC PHV 4.2 by rebuilding the 
valve with 0.020 inch diameter nitinol vvire (figure 59). 
TC PHV 4.2 represented a huge leap forward in preventing regurgitation with a 
mean of 5%, which was a 63% decrease over TC PHV 4.0 and was directly on target with 
the design requirements. An observation that affected the next iteration was motion of 
the base of the valve into the flow stream during systole, i.e. flow was lifting the stent off 
the wall of the tube with each forward stroke. This may have been the cause of the 
higher adjusted mean pressure drop of 28 mmHg, which was an 11 increase over TC 
PHV 4.0. TC PHV 4.2 was crimpable to 24 F. 
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Figure 59: TC PHV 4.2. 
9.3.8. TC PHV 4.3 
Prototype 4.3 was designed to address the phenomenon observed during LIIS 
testing of 4.2. TC PHV 4.2 was observed to have some weakness in the base stent to 
which the leaflet material was attached; evidenced by a deflection of the stent into the 
flow stream during systole. Therefore, an additional stent was placed in the base of the 
PHV (figure 60). The resulting design decreased the adjusted mean pressure drop ( 14.4 
mmHg) by 48% and the mean regurgitation (3.24%) by 35% compared to TC PHV 4.2. 
These values were directly on target for the design requirements. Additionally, this 
prototype was crimpable to 24 F (figure 61 ). 
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Figure 60: TC PHV 4.3, notice the additional stent in the base of the PHV. 
Figure 61: TC PHV 4.3 inside the 24 F slot of the French Scale block. 
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9.3.9. TC PHV 4.3.1 
The next prototype was designed to address crimpability. All other design 
parameters were held constant due to the stellar performance of TC 4.3 in the LHS test. 
The only design change was a reduction in the leaflet material thickness. Concurrently, 
the silicone aorta was further modified in order to produce a more compliant arterial 
model. The wall thickness of the silicone tube was decreased by 50%, then the ratio of 
elastomer to curing agent was increased, i.e. the curing agent mass was decreased with 
respect to the mass of the elastomer for each succesive SA (2.2=10:1; 2.3=12.5:1; 
2.4=16.67: 1; 2.5=25: 1 ). This resulted in a more elastic silicone polymer. By 
comparison, SA 2.0 was virtually non-compliant and SA 2.1 was about 95% stiffer than a 
healthy natural aorta, which exhibits approximately 8-10% strain with a 40 mmHg 
pressure change. As a result TC PHV 4.3.1 was tested inside the SA 2.1, 2.2, 2.3, and 
2.4. Each SA had increasing values of compliance with SA 2.4 being the most 
compliant. TC PHV 4.3.1 \vas successfully crimped down to 21 F. 
TC PIIV 4.3.1 had a mean adjusted pressure drop of 22 mmHg and a mean 
regurgitation of 4% in SA 2.1. In SA 2.2 it had a mean adjusted pressure drop of 24 
mmHg and a mean regurgitation of 9.4%. In SA 2.3 and 2.4 the testing could not be 
completed due to valve migration and prolapse, but mean pressure drop and regurgitation 
values of 12 mmHg and 6.3% and 9.5 mmHg and 13.5% respectively were recorded prior 
to failure. It seemed that the more compliant tubing was conducive to valve migration 
and the many tests endured by TC PHV 4.3.1 illuminated the lack of durability of the 
design as the leaflet material began to loosen in later tests. Additionally, the more 
compliant tubing seemed to contribute to an increased volume of leakage flow. 
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9.3.10. TC PHV 4.3.2 
With TC PHV 4.3.1 being crimpable to 21 F, the next iteration of the prototype 
was designed to be both crimpable to 21 F and to have the ability to function in a much 
more compliant silicone aorta. TC PHV 4.3.2 (figure 62) was manufactured using the 
new nitinol \\ire annealing plates so that the stents would have larger diameters. Greater 
stent oversizing was to address fixation in an SA with compliance equivalent to a natural 
healthy aorta. The distal stent was made with 0.020 inch diameter super-elastic nitinol 
wire, and the proximal two stents were the same type of wire at 0.015 inch diameter. 4-0 
Ethibond Excel suture was used to assemble the PHV. The leaflet material was 
fabricated using a 3x3 inch sheet of polyester fabric (Bard) and 8 ml of SIBS-toluene 
mixture composed of 15% SIBS by mass. The resulting leaflet material had a thickness 
of approximately 230 microns. The leaf1et material was cut into a 25x65 mm sheet and 
made into a cylinder using 4-0 Ethibond Excel suture to join the ends. 304 stainless steel 
0.040 inch thin-walled hypodennic tubing and Elmer's Krazy glue \Vere used to join the 
ends of the vvires to make stents. Once the PHV was assembled the leaf1ets were 
annealed in a 60°C own for at least two hours using stainless steel ball bearings in order 
to set a hemispherical shape into the material. TC PHV 4.3.2 was tested in the LHS using 
SA 2.1, 2.2, 2.3, 2.4. and 2.5. Unfortunately, the valve migrated during testing in each 
conduit except SA 2.1, the least compliant SA. In SA 2.1 it had an adjusted mean 
pressure drop during fonvard ilow of 26 mmHg and a mean regurgitant fraction of 11%. 
Therefore, overall it performed worse than TC PHV 4.3.1. The intended design 
improvements only served to decrease the performance of the PHV. Moreover. it \Vas not 
crimpable to 21 F. One more iteration followed in an effort to correct the situation. 
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More compliant conduits again seemed to correlate with higher regurgitation and in some 
cases lower pressure drops. 
Figure 62: TC PHV 4.3.2 
9.3.11. TC PHV 4.3.3 
The last TC PHV prototype fabricated was 4.3.3. TC PHV 4.3.2 was 
deconstructed and rebuilt as 4.3.3 (figure 63). Leaflet material was removed to decrease 
the height of the leaflet material and the amount of overlap of the material on the outer 
portion of the proximal stents. Additionally, a new suture technique was used to 
assemble the PHV in an effort to reduce the mass of suture knots around the outer 
perimeter of the PHV. The valve was tested in SA 2.5 only and it migrated during the 
first 100 bpm test. Prior to migration an adjusted mean pressure drop of 6.4 mmHg and a 
mean regurgitant fraction of 21.5% were recorded. Both TC 4.3.2 and 4.3.3 had lower 
pressure drops and higher regurgitation in the most compliant silicone aorta (2.5). The 
valve exhibited a relatively large closing volume during testing. 
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Figure 63: TC PHV 4.3.3. 
9.3.12. EDWARDS LIFE SCIENCES: SAPIEN (CRIBIER) 
In a fortuitous occurrence, an Edwards-Sapien (Cribier) stent was obtained for 
testing (figure 64). The SIBS-Dacron composite leaflet material was carefully attached 
to the stent utilizing the predrilled holes in the stent frame. A cuff was made to ensure a 
tight seal with the tube wall. The result was phenomenal performance. Sapien 
outperformed all other prototypes and rivaled the performance of the 25 mm diameter St. 
Jude bileaflet mechanical valve. The SS ball bearings and 60°C oven were again used for 
leaflet f01ming. The Sapien set the bar for the final performance of the TC PHV concepts 
in this proposal, with a mean pressure gradient during forward flow of 15 mmHg, and a 
mean regurgitant fraction of 1. 7%. 
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Figure 64: Edwards Life Sciences Sapien valve by Claiborne. 
9.4. HYDRODYNAMIC RESULTS 
Compiled LHS test results are shown plotted in charts 4 and 5. Chart 4 is a plot 
of cardiac output as function of regurgitation. We expect regurgitation to decrease as 
cardiac output increases. Data collected for rebuilt FJA-MCB PI-IV, Sapien, and the Jt. 
Jude valve were compared to TC PHV 2-4.3. In the cases of TC PHV 4 series, each 
prototype out performed the rebuilt FJA-MCB PHV. Each successive TC PHV was 
progressively better than the former as well. TC PHV 4.3 was statistically no different 
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than Sapien. Further iteration of the TC PHV 4 series were omitted from these graphs 
because testing of those valve took place in newer more compliant silicone aortas, which 
introduced new phenomena that will require further study in the future. 
40 
35 
30 
~ ~ 25 
z 
0 
i= 
;5 20 
13 
0:: 
::::! g 15 
0:: 
10 
5 
0 
0 
..._ St Jude 25 mm 
~~·~· FJA~MCB 
.,..._TCPHV2 
~TCPHV3 
-ll<-TC PHV 4 
·--+-TC PHV 4.2 
-+-TC PHV 4.3 
·-SAPIEN 
2 3 
PROTOTYPE PHV COMPARISONS 
4 5 6 7 
CARDIAC OUTPUT (Umin) 
9 10 
Chart 4: A comparison of valve perfom1ance is illustrated with a plot of cardiac output as 
a function of regurgitation. We expect regurgitation to decrease as cardiac output 
increases. This chart clearly shows the stepwise improvement in performance with 
prototype PHV with TC 4.3 having the best recorded performance when compared to 
Sapien and the St. Jude valve. 
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Chart 5: A comparison of prototype perfonnance via a plot of mean forward flow rate as 
a function of the calculated adjusted mean pressure drop across the valves. As in chart 4, 
a clear progression in PHV performance is illustrated as compared to the performance of 
the Sapien and St. Jude valves. Notably, each tc phv performed better than the rebuilt 
FJA-MCB valve. We expect an increase in pressure drop as the flow rate increases. 
Each silicone aorta utilized for hydrodynamic testing was tested alone in order to 
measure the intrinsic pressure drop of the conduit. Chart 6 illustrates those results. 
Oddly, no apparent pattern emerged in the group. Each SA had a different compliance 
value, but a clear correlation between compliance and the intrinsic pressure drop was not 
elucidated by the data. 
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SILICONE AORTA INTRINSIC PRESSURE GRAOIENT 
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Chart 6: The pressure drop measured across each silicone aorta without a PHV in place. 
The values shown were used as "'tube factors" (TF) to adjust the measured pressure drop 
across each PHV recorded during each LHS test, i.e. adjusted pressure= raw value- TF. 
Each successive model was more compliant than the former. The original configuration 
of the LHS was tested without a valve as welL and the value is noted by the "glass sinus" 
value (d=30 mm). Each SA had an inner diameter of 19 mm. 
The effective orifice area of each prototype was calculated using equation 20 in 
accordance with ISO 5840:2005. Matlab \Vas used for the calculations and the program 
can be found in the appendix. The minimum EOA required by the ISO standard for a 19 
~ 
mm tissue annulus diameter (TAD) was 0.70 em~. Each TC PHV surpassed that 
requirement as shown in chart 7. PHV 4.3.3 produced the largest EOA \vhen tested 
in the most compliant SA (2.5). The effect of altering the compliance is illustrated in 
chart 8. 
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Chart 7: ISO 5840:2005 effective orifice area for each prototype PHV. The EOA 
minimum requirement for a 19 mm tissue annulus diameter is 0.70 cm2• Each TC PI-IV 
prototype surpassed that requirement. The compliance of the SA had a significant effect 
on the EOA. The less compliant the SA; the lower the EOA. 
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Chart 8: The effect of increasing the SA compliance is illustrated by showing that one 
PHV can have significantly different EOA values as the test conduit compliance changes. 
This shows the ability of the Nitinol stent to confonn to changes in the conduit structure. 
Statistical analysis of the hydrodynamic data using one-way ANOV A of means 
via SPSS 13.0 showed that each PHV prototype was significantly different in terms of 
adjusted mean pressure drop across the PHV and mean regurgitation fraction (p<O.OOl ). 
Additionally, each model of silicone aorta was significantly different in terms of the 
mean pressure drop across the conduit without a valve in situ (p=O.OO 1 ). 
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AN OVA 
Sum of 
Squares df Mean Sauare F Sig. 
Adjusted Mean Pressure Between Groups 8869.721 9 985.525 6.302 .000 
Drop During Forward Within Groups 17046 108 109 156.386 
Flow(mmHg) Total 25915.829 118 
Regurgitation (%) Between Groups 6559.560 9 728.840 26.701 .000 
Within Groups 2975.294 109 27.296 
Total 9534.854 118 
Table 4: SPSS 13.0 one-way ANOV A shown. The means of each parameter of each 
valve were significantly different (p<O.OO 1 ). 
9.5. FORCE TESTING RESULTS 
During compression testing a diameter of 19 mm was reached when the linear 
displacement was 0.28 mm in a range of -6 to +6 mm. The measured force value 
recorded at that instant was used in the radial force and stifTness calculations because the 
PHV were designed to reside inside 19 mm diameter conduits, so the force applied to the 
conduit wall by the PHV at that diameter was the parameter of interest. Overall, chart 9 
showed a positive linear trend in the applied force as the displacement increased. The 
Sapien compression test was ended prior to the 12 mm displacement being reached 
because it had reached a load of 12.5 Nand the Teflon material began to stretch around 
the Sapien valve rather than crushing the valve. In the case of Sapien alone, a less elastic 
material would have been needed to perform the test to 12 mm of displacement. 
However, this was not pursued because Sapien displayed a radial force at -3 mm of 
displacement 2.62 times greater than TC PHV 2 at 0.28 mm of displacement. 
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TC PHV SERIES 4 RADIAL COMPRESSION TEST 
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Chart 9: Results from Bose ELF 3200 radial compression tests. 
Chart 10 shows the calculated radial force for each PHV prototype tested. By 
comparison. using equation 28. an artery vvith 100 mmHg of internal pressure exerts a 
radial force of about 0.333 N/mm. The average length of each PI-IV prototype was 30 
mm. so the radial force applied to the PHV by the artery would be about 10 N. 
Therefore, the results in chart 13 show that under normal conditions each TC PHV would 
be able to overcome the crushing force of the artery and dilate its lumen. 
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PHV RADIAL FORCE 
{at Diameter= 19 mm) 
PHVMOOEL 
Chmi 10: Radial force for each PHV prototype at a diameter of 19 mm, which 
corresponds to the inner diameter of the silicone aorta used for hydrodynamic testing. 
The stiffness of each valve tested was calculated via equation 31 and the results 
are shown in chmi 11. This value was designed to characterize the material properties of 
the PI-IV as a whole in terms of its ability to resist cmshing for comparison to other types 
of stents and materials. 
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PHV STIFFNESS 
PHV MODEL. 
Chart 11: PHV stiffness at a diameter of 19 mm as defined by Duerig et al. 2000. 
Stiffness, k, is a material constant that can be universally compared to other stent borne 
valves. 
A stress-strain curve was constructed for the PTFE material used during the 
compression tests (chart J 2). The purpose of during so was to calculate the Young's 
modulus and to show that the force required to plastically deform the material greater 
than 6 N. which \Vas not surpassed by any test valve, except Sapien. 
105 
16 
14 
12 
-10 
Ill 
a. 
!. 
w 13 w 
1.1.1 
0:: 
1-
w 6 
4 
2 
0 
0% 
PTFE SHEET ELASTIC MODULUS 
{Used for PHV Radial Force Tests) 
£::::53.3 MPa 
40% 
STRAIN 
Chart 12: The elastic modulus of the Teflon material used for the PIIV compression tests. 
This has been included in order to illustrate that fact that the material could not have 
exhibited defonnation that could have skewed the compression test results. The elastic 
range of the material is much smaller than Nitinol. 
The fixation force test data is plotted in chart 13. Points of initial slippage are 
marked. Only TC PHV 4 did not exceed the required 3 N limit. which is equivalent to 80 
mmHg of diastolic pressure on the valve in situ. 
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TC PHV SERIES 4 AXIAL LOAD TEST 
(Inside Wetted Silicone Aorta) 
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Chart 13: Results from Bose ELF 3200 axial tensile tests. A fixation force greater than 3 
N was considered success. (Diastolic pressure. 80 mmHg. exerts approximately 3 N of 
force on the PHV. Fluid shear stress \vas not considered.) 
9.6. COMPLIANCE RESULrS 
The compliance of hydrodynamic test chambers for prosthetic valves is 
governed by ISO 5840:2005 where high compliance is defined as 0.32 %/mmHg and low 
compliance is defined as 0.09 %/mmllg. Therefore, efforts were made to meet or exceed 
the minimum requirements of the standard. Determining the compliance of the silicone 
aortas was the first step since they were designed to be analog animal aortas. The results 
of the compliance tests are shown in chart 14. When the Windkessel model was used to 
calculate the LHS systemic compliance \Vith each SA in situ no real pattern emerged, but 
the system did appear to be generally less compliant with the silicone aortas when 
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compared to its original configuration (chart 15). Overall, the silicone aortas produced 
"lo\v'' compliance results during hydrodynamic testing. I Iowever, systemic calculated 
compliance may have been "lo\v", but the actual change in diameter of each SA during 
the cardiac cycle of the LHS could be visualized. Interestingly, the bench-top 
compliance of SA 2.5 was calculated to be 0.208 %/mmHg, but photographic analysis of 
SA 2.5 in action inside the LHS showed about a 7.4% change in diameter with a pulse 
pressure of 160 mmHg, which turned out to be a compliance of 0.05 %/mmHg. So the 
LHS system somehow damped the intrinsic compliance of the SA by 76%. 
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Chart 14: Compliance values measured and calculated on the bench top. The natural 
aorta value was calculated by assuming a 9% diameter change with a pulse pressure of 40 
mmHg. According to ISO 5840:2005, C=0.09 is a "low'' compliance value, whereas 
C=0.32 is a "high" compliance value. 
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Chart 15: Windkessel model results for LHS systemic compliance using each SA and the 
original configuration using the glass sinus. No real pattern emerges other than the 
obvious near .. naturar' compliance of the LHS obtained \Vhile employing the 
manufacturer's specified configuration. 
9.7. DELIVERY SYSTEM RESULTS 
The PHV delivery system functioned as intended overalL The steering 
mechanism deflected the catheter tip into the center of the test conduit when it was pulled 
as shown in figure 65. The TC PHV 4.3.1 was successfully loaded into the 21 F lumen 
catheter using the crimping tool (figure 66). The model aorta \Vas utilized for the test 
and successful deployment of the PHV into the silicone aorta was performed (figure 67). 
Once deployed, the PHV expanded in place as intended. However, loading and 
deployment of the PHV was performed with difficulty because of the tight fit of the PHV 
inside the catheter. The catheter itself kinked when it navigated the curve of the tube. 
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The glue used to hold the sheath retraction spool in place failed due to the high force 
needed to retract the sheath. A mock aortic flow loop was designed and attached to the 
LHS and a dynamic PHV delivery and deployment test was performed. The PHV was 
successfully deployed into the SA during that test. 
Figure 65: Photos showing the remote deflection of the catheter tip using the catheter 
hand piece. The tip moved off the tube wall and into the center of the tube using the 
steering mechanism. 
Figure 66: Crimping tool being used to load TC PHV 4.3.1 into the 24 F OD - 21 F ID 
catheter tubing prior to the delivery and deployment test. 
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Figure 67: Sequential deployment ofthe TC PHV 4.3.1 is shown inside the polycarbonate 
tube and SA 2.4 or the analog amia as it was. 
10. DISCUSSION 
The current '"gold-standard" in heart valve prostheses are mechanical and tissue 
valves. which are implanted via highly invasive. traumatic, and costly open-heart surgical 
procedures. Mechanical valves, typified by the St. Jude bilcaflct pyrolitic carbon valve, 
are highly durable but also highly thrombogenic in vivo. Recipients of mechanical valves 
must endure a lifetime of risky anticoagulant drug therapy. Conversely. tissue valves are 
less durable and less thrombogenic. As such, tissue valve recipients may require only 
temporary or mild anticoagulant drug therapy. Therefore, mechanical valves are 
typically reserved for patients who can tolerate the anticoagulant drugs and who are 
younger than the age of 65, and tissue valves are generally reserved for people over the 
age of 65 or for individuals who would be at greater risk for complications from 
anticoagulant drugs. Since their invention and commercialization over 30 years ago, 
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these two modalities of heart valve disease treatment have seen relatively little change, 
and neither is ideal. Therefore, there exists opportunity for improvement in the existing 
technology and creation of new technology to be used as alternative therapy. Catheter 
deliverable or percutaneous heart valve (PHV) prostheses have been developed recently 
and promise to be a safe and effective minimally invasive alternative to open-heart valve 
replacement surgery. There has been great professional interest among interventional 
cardiologists in PHV technology since the first successful pulmonary PHV human trial by 
Bonhoeffer et al. in 2000. and the first successful aortic PHV human trial by Cribier et al. 
in 2002. [20,24] PHV development has rapidly advanced since then primarily in the 
hands of private industry and physicians. All of the relevant PHV s in development and in 
human trials are based on tissue valves, which are known to be inferior in tern1s of 
durability, and the effects of crimping and deploying tissue PHVs has just begun to be 
investigated. [33,56] Moreover. the lack of rigorous engineering analysis during 
development of the current PHV s is becoming evident, e.g. there has been a reported 
21% rate of stent fracture in the Medtronic Melody PHV. [90] 
The purpose of this work was to develop and evaluate an artificial aortic PHV 
with superior characteristics to the current tissue based PHV s, and to develop an 
accompanying delivery system. It has long been a goal of researchers to develop a 
prosthetic heart valve which incorporates the positive attributes of both tissue and 
mechanical valves into one product while eliminating their weaknesses. This concept 
was extended to Pl:IV s during the course of this work. Recent developments in synthetic 
heart valve materials have been promising and were a motivating factor. 
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The PHV developed during the course of this work utilized a state-of-the-art 
super-biostable polymer and polyester fabric composite valve material developed at FlU. 
[58] The stent \Vas manufactured using super-elastic Nitinol wire, and the PHV was 
assembled using braided polyester suture and stainless steel hypodermic tubing. The 
PHV was designed to be self-expanding, to function as a trileaf1et valve, and to remain in 
place via spring force and friction. The TC PHV series 4, the final chosen design, was 
based upon an amalgam of current PHV designs and information found in literature. The 
PHV was no less than 30 mm in length with a valve height of 1 5 mm. The proximal 
portion of the PHV "vas composed of two sinusoidal stents coupled to the valve 
composite material, and the distal portion \vas composed of one 50% larger diameter wire 
and stent for fixation. These dimensions were derived from the design constraint of a 19 
mm valve diameter, vvhich corresponded to that of a small adult and the animal model. 
The valve construction was based upon anatomical studies that showed that the aortic 
valve functioned like a collapsing tube, and as such the material was formed into a 
cylinder and tethered at three equidistant points on the proximal stents in order to form a 
near natural trileaflet valve. ( 1 0] The valve material thickness was made as thin as 
possible (between 200 and 230 microns) in order to facilitate crimping, and because the 
leat1et material thickness \vas inversely proportional to its flexibility. Nitinol was chosen 
as a stent material due to its superior elasticity, its biocompatibility, and its tendency to 
exert a chronic outward force over its entire working life \vhen oversized with respect to 
the vessel in "Which it resides. While stainless steel or other rigid alloy stents may exert a 
higher initial radial force, a Nitinol stent will tend to slowly reshape the lumen of the 
vessel in which it resides to a larger diameter due to its chronic outward force. [60] 
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Furthermore, a less elastic alloy could be reduced in diameter over time by the cyclic 
loading applied by the muscular arterial wall and the dynamic aortic annulus. The 
diameter of the Nitinol wire used in the final prototype was chosen based upon 
experimental results. A larger diameter wire had a higher stiffness, and the tear-drop 
shaped bends formed in the distal stent increased the overall stiffness. The crimped size 
of the stent was directly related to the wire diameter and the number of bends in the wire, 
therefore those parameters were minimized in the design. [59] As a result each TC PHV 4 
series was crimpable to 24 F or less, and the distal stent had 50% greater wire and stent 
diameter than the proximal stents. Additionally, the Contraction Limit formula created 
by FJA predicted a contraction limit of 30 F for TC PHV 4.3.1, however testing proved 
that the valve was crimpable to 21 F. [ 69] 
It quickly became apparent upon replicating prior hydrodynamic tests, which 
employed porcine aortic segments, that a new model and method of testing PHV s in the 
lab would need to be created. [69] The goal was to increase in vitro test quality control 
and to eliminate the variability, costs, hazards, and labor akin to in vitro animal blood 
vessel models. The initial concept was to simply replace the porcine aorta with a 
transparent silicone tube of equivalent size while maintaining the use of the fixture 
developed by FJA. However, this still allowed some variability via the fit of the FJA 
fixture to a silicone tube and the marriage of the two inside the LHS. Moreover, the 
initial silicone tube mold was less than ideal. In light of those limitations inspiration 
came in the form of a single solid molded silicone tube that could fit, with optimal 
precision, inside the LHS without modification of the LHS itself, while eliminating the 
extra components required by the FJA apparatus. The initial SA (2.0) was designed to fit 
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and function inside the LHS vvithout regard to compliance. Once proof of concept had 
been established. the compliance of the SA was manipulated. This was accomplished via 
changing the wall thickness and altering the mixture ratio of silicone elastomer to curing 
agent. The silicone elastomer tubes proved to be adequate analogs to porcine aortas. with 
the advantages of transparency. ease of manufacture. consistent dimensions, and 
consistent test results. However. thev clearly altered the dvnamics of the LHS insofar as 
.,r ., ... ~ 
compliance and resistance of the system. The LHS was designed to be used for valve 
testing precisely as constmcted by the manufacturer. The first and most important 
observation was that the SAs had an intrinsic pressure gradient \vithout a valve in situ. 
This gradient was measured, averaged, then subtracted from the raw pressure gradient 
data collected during PHV hydrodynamic testing. The subtraction of this "tube factor" 
allowed comparison of the data to the St. Jude valve and was a more accurate 
measurement of the pressure gradient caused by the PHV itself. Later hydrodynamic 
prototype results showed that highly compliant silicone aortas introduced new flow and 
pressure phenomena such as an increased closing volume, decreased transvalvular 
pressure gradient, increased stroke volume and cardiac output and increased effective 
orifice area. During hydrodynamic testing using the most compliant SA (2.5) an 8% 
diameter change was observed with a pulse pressure of 140 mml-lg. This vvas less than 
the bench top value measured. Therefore. the U1S enclosure must have reduced the SA's 
compliance in some manner. Additionally, a reduction in the fixation abilities of the 
PHV was observed at high f1ow rates. Cumulatively, these results made interpretation of 
chart 15 difficult and called into question the efficacy of the Windkessel Model employed 
for modeling the LHS. i.e. the relationship between the compliance of the SA alone and 
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the compliance of the LHS as a whole with the SA in situ was not readily apparent. 
Unfortunately, these observations were made near the end of the project and would need 
to be addressed in future work. As such, the hydrodynamic test results reported in this 
work for comparison ofPHV performance to the competition omitted the results obtained 
during testing ofPHVs in the highly compliant SAs. 
The delivery system was designed to deliver and deploy the PHV retrogradely via 
peripheral arterial access. The consensus in the medical literature indicated that such an 
approach was ideal. The catheter tip was designed to be atraumatic to the arterial 
endothelium and to allow the passage of a guidewire through the lumen of the catheter. 
The catheter was designed to have an outside diameter of no more than 24 F and to be 
stiff enough to push and flexible enough to navigate the tortuous arterial pathway. The 
inner parts of the catheter were designed to be a framework that would allow remote 
deflection of the catheter tip for precision positioning and retraction of the sheath for 
PHV deployment. The hand piece was designed to function as the remote control 
mechanism for PHV deployment and catheter tip steering. The crimping tool was 
designed to facilitate crimping and loading of the PH V into the delivery catheter. These 
design features were recognized as being desirable based upon a review of the literature. 
Moreover, Edwards Life Sciences had recently developed a steerable PHV catheter for 
use with its Sapien PHV. [ 1,34 J The prototypes designed and fabricated functioned as 
intended during bench-top testing and during dynamic delivery and deployment testing 
performed inside a mock aortic f1ow loop that was attached to the operating Vivitro 
Systems, Inc. Left I Ieart Simulator. However, the FEP tubing used as a catheter was less 
than ideal in that it kinked when navigating the curvature of the analog aorta. 
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Additionally, it took a considerable amount of force (not measured) to retract the catheter 
sheath due to the tight fit of the PI IV inside the 21 F lumen of the catheter. 
Unfortunately, there was neither the time nor the budget to optimize the delivery system 
design. However, for the purposes of this work, the delivery system was a success. 
The hydrodynamic test results for each prototype PHV were compared to one 
another, to a St. Jude 25 mm diameter bileaflet mechanical valve, and to an Edwards-
Sapien PHV fabricated with the composite leaflet material. Among the TC PHV 
prototypes, 4.3 was the best performer. One-way ANOVA showed that the mean 
performance of each valve was significantly difTerent (p<O.OOl) when compared as a 
group. Moreover, Tukey's post hoc test indicated that there was no significant difference 
between Sapien and TC PHV 4.3 (p=l.OOO). nor betvveen the St. Jude valve and TC PHV 
4.3 (p=0.6ll). Additionally, there was no clinical difference between TC PHV 4.3 and 
the St. Jude valve nor the TC-Sapien PHV. [68] As an aside. the nonnegative slopes of 
the curves shovvn in chart 4 could be attributed to the very low resistance of the LHS at 
high flow rates during those particular tests. In other words, the particular PHV could not 
achieve high flow rates without there being very low peripheral flow loop resistance. 
This allowed the valve to open during diastole \Vhen the t1ow was oscillating thereby 
causing an increase in regurgitation. These statistical results indicated that the TC PHV 
was at least comparable to competitors. 
A review of the literature indicated that a mid-term study of the Sapien PHV 
showed a mean transvalvular pressure gradient of 10 mmHg with an average valve area 
of 1.7 cm2, and 0 to +2 regurgitation. [64] TC PHV 4.3 had an adjusted mean pressure 
drop of 14.4 mmHg with an EOA of 1.14 cm2 and a regurgitation of 3.24o/(>, \vhich is 
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essentially 0 on the ACC scale. Both used 24 F catheters for delivery. When compared 
to a 30-day trial of the Core Valve where a mean pressure gradient of about 10 mmHg and 
regurgitation of 0 to was reported, again TC PHV 4.3 compares favorably. [66] 
Notably, the delivery catheters used by the CoreValve were 21 and 18 F. However, a 
limitation to these comparisons was that the TC PHV data was entirely in vitro and the 
literature data was entirely clinical. To date. there are no knmvn relevant in vitro studies 
available for comparison. 
The fixation and radial forces exerted by the PHV prototypes was tested with a 
Bose ELF 3200. The fixation test was modeled after a study published by Zhou et al. 
\vherein they deployed an abdominal aortic aneurysm stent graft into a segment of bovine 
aorta and measured the force required for slippage. (63] In this work one of the silicone 
aortas was utilized in lieu of a bovine aortic segment and the Bose machine was more 
sophisticated than the force gauge utilized by Zhou. Additionally, the SA was wetted 
with the blood analog solution used in hydrodynamic testing of the PHVs. The results 
showed that the TC series 4 PHV s could resist up to 6 N of force prior to slipping. This 
translated into the PHV being able to approximately resist up to 160 mmHg of diastolic 
pressure, which is \:veil above nom1al physiological diastolic pressures even for 
hypertensive individuals. The radial force tests also utilized the Bose ELF 3200, but the 
apparatus was different. A piece of 0.015 inch thick PTFE sheet was used to create a 
loop in which pulling the free ends caused the loop diameter to contract. The starting 
diameter was set to 21 mm in each test and the linear travel of the system was set to 12 
mm, which translated into an 18% decrease in the loop diameter during testing. The 
forces recorded precisely when the loop reached 19 mm in diameter was used to calculate 
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the radial force exerted by each PHV tested. The theoretical radial force calculated for a 
typical artery of30 mm in length was found to be approximately 10 N, and the test results 
for the TC series 4 PHVs more than doubled that value. [601 Therefore, the PHV was 
predicted to be able to overcome the crushing force of the aorta and expand to the desired 
diameter or to the elastic limit of the vesseL 
11. CONCLUSION 
A novel catheter deliverable artificial aortic heart valve prosthesis and delivery 
system were developed and evaluated. The results indicate that the best perfonning PHV 
prototype, TC PHV 4.3, has proven the feasibility of this technology by showing 
equivalence, and in some cases superiority, to the existing PHV technology currently in 
clinical trials. Specifically. the in vitro hydrodynamic test results have proven that TC 
PHV 4.3 was not significantly different (p>0.05) from the CoreValve, the Sapien PHV 
(both tissue and polymer composite). nor the 25 mm St. Jude mechanical valve. 
Additionally. The delivery system functioned as intended by delivering and deploying TC 
PHV 4.3.1 on the bench top and inside the functioning Vivitro Systems, Inc. Left Heart 
Simulator. It had the capability of remote catheter tip deflection and PHV deployment 
and had a maximum profile of 24 F. The accompanying crimping tool was able to crimp 
and hold the PHV in a crimped conformation f()r the facilitation of PHV loading into the 
delivery catheter. Furthermore, the silicone aortas developed for in vitro hydrodynamic 
testing proved to be sufficient analogs to animal am1ic segments, and achieved the goals 
of providing quality control, customizable compliance, and eliminating waste, cost, labor 
and hazards of animal tissue models. The force testing performed on the PHVs indicated 
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that the TC series 4 PHV s could resist up to 160 mmHg of diastolic pressure loading and 
more than twice the estimated 10 N crushing force of a typical artery. 
Future work will include further investigation of the effects of highly compliant 
silicone aortas on the Vi vitro Systems, Inc. Left Heart Simulator and the function of the 
PHV prototypes and consequent optimization of the in vitro hydrodynamic testing model; 
durability testing and PHV design optimization; in vitro biocompatibility testing; 
computer modeling of the PHV; delivery system optimization and quantitative testing; 
and animal testing. 
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13. APPENDICIES 
MATLABCODE 
HYDRODYNAMICS CALCULATOR 
% Vivitro Systems LHS Heart Valve Hemodynamics Parameter Calculation Program 
%Written by Ted Claiborne July 2007 
%Revised August 22, 2007 
%--------------------------------------------------------------------
clear all; 
close all; 
clc; 
load -ASCII 703.txt;% Load data into a matrix in the Workspace: 
%CHANGE FILE NAME FOR EACH NEW DATA FILE (ex: "123.txt") 
ch 1 = X703 ( :, 1 ); % Assign data from text file to variables and ere at specific data arrays 
ch4= X703 (:.4);% ENTER FILE NAME HERE AS WELL, AFTER THE "X" 
ch3= X703 (:,3); 
Half HR=70/2 %ENTER HEART RATE NUMERICAL VALUE FOR DATA SET 
HERE BEFORE THE "/" 
Target_ C0=3 %ENTER TARGET CO NUMERICAL VALUE HERE 
A=size(ch3);% Find range of data array 
B=size( ch4 ); 
G=size(chl); 
A=A(l);% Define array starting point and value 
B=B(l); 
G=G(l); 
C=zeros(l ,A); % Set up data matrix for calculations 
D=zeros( 1 ,B); 
E=zeros( 1 ,A); 
H=zeros(l ,G); 
i=l; %Define counting variables 
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1. 
' 
while i<=B %Create matrix of positive channel 4 values 
\Vhile (i<=B) & (ch4(i)>O)% Collect all positive values 
j=j+ 1; 
D(j)=ch4(i); 
i=i+ 1; 
end 
while (i<=B) & (ch4(i)<O)% Ignore negative values 
i=i+l; 
end 
end 
u=l; %define counting variables 
p=O; 
while u<=G %Create a matrix of ch 1 values 
p=p+l; 
H(p )=chI (u); 
u=u+l; 
end 
chl_max=max(H):% Determine max chl value 
chl_min=min(H);% Determine min chi value 
MAP=(max(H)+2*min(H))/3 %Calculate MAP from chi matrix 
sum_ch4=sum(D): %Calculate sum ofD matrix 
pos_mean_press drop_ch4=sum(D)/j %Calculate and output channel4 positive mean 
pressure drop (mmHg) 
max_press_drop_ch4=max(D) %Find and output maximum channel4 value (mmHg) 
mean __ flow_rate=mean(ch3) %Calculate and output CO from channel3 (Limin) 
n= 1; %Define counting variables 
1n=l, 
while n<=A %Create matrix \vith positive channel 3 values 
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while (n<=A) & (ch3(n)>.5)% Collect ch3 values above 0.5 
m=m+l; 
C(m)=ch3(n); 
n=n+l; 
end 
while (n<=A) & (ch3(n)<.5)% Ignore ch3 values below 0.5 
n=n+ 1; 
end 
end 
stroke_volume=(trapz(C)*.005*(1000/60))/Half HR (%Calculate and output forward tlow 
volume (ml) 
sum_ch3=sum(C); %Calculate the sum of matrix C 
mean_forward_f1ow_ratc=sum(C)/m %Calculate the mean of matrix C 
q=l; %Define new counting variables 
w=l; 
cardiac_ output=strokc _volume* Half_HR *211 000 
while q<=A %Create matrix of negative channel 3 values 
while (q<=A) & (ch3(q)<(-.5))% Collect ch3 values below -0.5 
w=w+l; 
E(w)=ch3( q); 
q=q+l; 
end 
while (q<=A) & (ch3(q)>(-.5))% Ignore ch3 values above -0.5 
q=q+l; 
end 
end 
leakage_ tlow _ volume=(trapz(E)* .005 *(1 000/60) )/Half_ HR % Calculate leakage f1ow 
volume (ml) using integration 
v=l;% Define new counting variables 
k=l; 
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F=zeros(l,B):% Define nevv matrix 
while v<=A %Create new matrix data set linking positive ch3 values to ch4 values 
while (v<=A) & (ch3(v)>.5) %In order to obtain a better delta P value we must ignore 
small oscillations around zero. 
k=k+ 1; Collect ch3 values above 0.5 
F(k)=ch4(v); 
end 
\Vhilc (v<=A) & (ch3(v)<.5)% Ignore ch3 values below 0.5 
v=v+l; 
end 
end 
ch4_sum=sum(F); %Calculate the sum of matrix F 
mean _press drop_ during_ forward_ flow_ ch4=sum(F)/k %Calculate the pressure drop 
accross the valve during forward flow 
Qrms=norm(C)/sqrt(m) 
effective orifice arca=(Qrms*( 1 000/60))/(51.6*(sqrt(mean _press_drop_during_forward 
- --
_flow _ch4/1.133))) 
WINDKESSEL MODEL 
ERROR FUNCTION 
function model_ error=error _fun(x); 
global yout tout Y R C; 
%load experimental data 
load TC707.txt; 
%define variables 
Y = TC707 ( 1 : 100 1,1 ): %pressure data matrix 
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R=x(l ); %compliance 
C=x(2); %resistance 
[tout,yout]=sim('wind_model_ted',[O:l/200:51); %tout and yout generated by simulink 
model 
length(Y); 
length(yout); 
model_error=Y-yout; %define function 
hist(model_error) 
OPTIMIZATION PROGRAM 
%windkesselleast squares curve fitting program using simulink model 
clc; 
clear all; 
close all; 
global yout tout Y R C; %define global variables 
wind model ted: 
- -
%load experimental data file 
load TC707.txt; 
%define variables 
Y=TC707(1: 1001,1 ); %pressure data 
xO=[.l .1]; %initial guess for Rand C values 
R=xO(l ); %initial value for R 
C=x0(2); %initial value for C 
Po=Y(l); %initial condition for simulink integrator 
ub=[20 20]; %upper bound for estimates 
lb=[O 0]; %lower bound for estimates 
[ x,resnorm ]=lsqnonlin( @error_ fun,xO,lb,ub) %least squares function 
R=x(1)*60/1000 
134 
C=x(2) 
%plot results 
figure 
plot(tout, Y,'.', tout, yout); 
xlabel ('time ( s )') 
ylabel('pressure (mml:Ig)') 
legend('data', 'fit') 
SOPs 
SOP 01 
1. Title: Fernando Jaramillo Arbel<iez (FJA) Modified-Central Coaptation-Forward 
and Backward Hooks (MCB) Catheter Based Heart Valve (CBHV) 
Manufacturing Process 
2. Scope: This document is intended to describe the manufacturing process for the 
FJA-MCB percutaneous heart valve (PHV) design. 
3. Author: Thomas E. Claiborne, III 
4. Materials: 
4.1 Small Parts, Inc. Super-Elastic Nitinol Wire 0.019 inch diameter by 36 inches 
long Part# NW-019-36 (2 each) 
4.2 Small Parts, Inc. Hypo Tube Thin-Walled 304 Stainless Steel 0.058 inch OD. 
0.047 inch ID Part# HTX-17T-36 (1 each) 
4.3 PET \voven fabric (Joanne Fabrics) 
4.4 SIBS Polymer (Innovia, LLC) 
4.5 Toluene Solvent 
4.6 Glass jar 
4.7 Stirring rod 
4.8 Braided Polyester Suture (3-0 Ethibond Excel from Ethicon) 
4.9 Aluminum Drying Plate 
4.10 Water 
4.11 Aluminum foil 
4.12 Elmer's Krazy Glue 
5. Equipment 
5.1 Fume Hood 
5.2 Stirring Plate 
Furnace with temperature range to at least 600 degrees Celsius 
5.4 Needle-Nose Pliers 
5.5 Wire Cutters 
5.6 Phillips and Flat-Head Screw Drivers 
5.7 5-Gallon Bucket 
5.8 Furnace Gloves 
5.9 Furnace Tongs 
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5.10 High speed rotary cutting tool 
5.11 Eye protection 
6. Nitinol Annealing Procedure 
6.1 The Nitinol wire must be annealed in a two-step process to obtain the desired 
shape. 
6.2 The Nitinol wire must be constrained in the first FJA wire forming mandrel. 
6.3 Thread the Nitinol wire on the first mandrel as shown in figure 1 and constrain 
it with the end-plate and the wing-nut and washer. 
6.4 While threading the Nitinol wire keep it taught by tensioning it with the 
needle-nose pliers while holding it in position on the mandrel with your hand. 
6.5 The wire is very elastic and will try to spring off the mandrel if not constantly 
constrained. 
6.6 Attach the constraining plates as shown in figure 2. 
6. 7 Fill a 5-gallon bucket about 2/3 full with water and bring it to the furnace. 
6.8 Locate furnace gloves and tongs and eye protection. 
6.9 Place the mandrel as assembled in figure 2 into the furnace. 
6.1 0 Set the furnace temperature to 500°C. 
6.11 Once the furnace has reached 500°C soak the assembly at that temperature 
for 5 minutes. 
6.12 CAUTION! EXTREML Y HOT! After 2 minutes of soaking at or above 
500°C CAREFULLY remove the mandrel using the tongs while wearing the 
furnace gloves. 
6.13 Quench the mandrel in the water bucket immediately. 
6.14 When the mandrel is cool to the touch, dry it off to prevent oxidation. 
6.15 The Nitinol should look blue in color. 
6.16 Remove the constraints and remove the Nitinol wire from the first 
mandrel. 
6.17 Placed the Nitinol wire on the second mandrel as shown in figure 3. 
6.18 Constrain the wire to form the hooks as shown in figure 4. 
6.19 Repeat steps 6.9-6.16 (The furnace need not be cooled to room 
temperature for this step.) 
6.20 The Nitinol wire should look like the one shown in figure 5. 
6.21 Repeat steps to manufacture a second Nitinol wire. 
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Figure l: Threading pattern for Nitinol wire. Copper wire is shown here for 
illustrative purposes. 
Figure 2: First mandrel with constraints. 
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Figure 3: Second FJA mandrel. This is used to form the hooks of the MCB valve. 
Figure 4: Second FJA mandrel with constraints. The bottom 3-fingered constraint 
plate lifts the wire loops off the mandrel at a certain angle, and the top 3-fingered 
constraint plate folds the wire loops over onto the center constraint plate. Place 
all screws (not shown). 
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Figure 5: The final shape of the annealed Nitinol wire. 
7. Stent Fabricating Procedure 
7.1 Cut the Nitinol wire at each bent loop as shown in figure 6. 
7.2 Trim each cut so that a small hook is fom1ed. 
7.3 Cut 6 pieces of hypodermic tubing with the rotary cutting tool each about 1 
em long and use them to join the cut pieces ofNitinol wire. See figures 6and 9 
for reference. (Use eye protection) 
7.4 Crimp each piece of hypo tubing and apply Elmer's Krazy Glue to the lumen 
of the hypo-tubing. 
7.5 The final stent should be composed of 6 N-shaped segments with alternating 
hooks. 
8. Leat1et Fabrication Procedure 
8.1 CAUTION! TOLUENE IS HIGHLY FLAMABLE AND NOXIOUS. THE 
FUME HOOD MUST BE UTILIZED. 
8.2 Inside the fume hood, mix 5 grams of the SIBS polymer with toluene 15% by 
mass in a clean jar. 
8.3 Place the jar onto the mixer with a stirring rod and leave until the SIBS is 
dissolved. 
8.4 Affix the PET fabric to the drying plate (figure 7). 
8.5 Use aluminum foil as a gasket betvveen the plate and the constraining lid. 
8.6 Tightly constrain the fabric onto the drying plate. 
8.7 Using a pipette, pour the SIBS solution onto the fabric in the drying plate. 
Leave the assembly in the fume hood until it is dry. 
8.8 Remove the fabric from the drying plate and cut it into three 25 mm strips. 
8. 9 Cut off the excess fabric. 
8.10 Cut each strip into the shape shmvn in figure 8. 
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Figure 7: Drying plate. 
Figure 8: Pattern for MCB valve leaflet created by FJA. 
9. Valve Assembly 
9.1 Suture the leaflets onto the valve stent using the Ethibond suture. 
9.2 Be sure to make a small cuff at the base of the valve. 
9.3 The suture technique is subjective. 
9.4 The final product is shown in figure 9. 
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Figure 9: F JA MCB Valve. 
SOP02 
1. Title: Vivitro Systems, Inc. Superdup'r Left Heart Simulator (LHS) Silicone 
Aorta (SA) Manufacturing Process 
2. Scope: This document is intended to describe the manufacturing process for the 
author's design of an artificial aorta for use in the Vivitro LHS for delivery and 
hydrodynamic performance testing of percutaneous heart valves (PHV). 
3. Author: Thomas E. Claiborne, III 
4. Referenced Documents: 
4.1 Solid Works Drawings by Claiborne ofthe SA Mold. 
4.2 "Information About High Technology Silicone Materials: Sylgard 184 
Silicone Elastomer, Base & Curing Agent" by Dow Coming 
5. Materials: 
5.1 Dow Corning Sylgard 184 Silicone Elastomer Base 
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5.2 Dow Corning Sylgard 184 Silicone Elastomer Curing Agent 
5.3 Isopropyl Alcohol 70% 
6. Equipment 
6.1 Low Temperature Oven 
6.2 Vacuum Chamber 
6.3 Scale 
6.4 Weighing/Mixing Container 
6.5 Stirring rod/Spatula 
6.6 Paper Towels 
6. 7 Flat head scre\v driver 
6.8 Hexagonal Wrenches 
7. Procedure 
7.1 Determine the ratio of curing agent to elastomer desired. 
7.2 Determine silicone tube the wall thickness desired. 
7.3 Make sure the mold is clean and dry (Figure 1 ). 
7.4 Put the two halves of the mold together by aligning the dowel pins (Figure 2). 
7.5 Insert the 4 larger screws, but do not completely tighten yet. 
7.6 Measure 50-60 grams of Sylgard 184 Silicone Elastomer Base in a mixing 
container. 
7.7 Add 5-6 grams of Sylgard 184 Silicone Elastomer Curing Agent for a standard 
10:1 ratio as recommended by the manufacturer. Figure 3 shows the scale 
used. 
7.8 Stir mixture until thoroughly mixed. 
7.9 Place the mixing container into the vacuum chamber and set to 15-20 inHg. 
Leave until all air is removed from the mixture. 
7.10 Pour the air-free Sylgard mixture into the mold. 
7.11 Slowly insert the mold spacer/pin into the mold until the top is flush with 
the mold. 
7.12 Wipe off all overflowing Sylgard. 
7.13 Insert the spacer screws. 
7.14 Tighten all screws. 
7.15 Place the mold in a location where it will not be disturbed. 
7.16 Allow the Sylgard to cure at room temperature for 24-48 hours. 
7.17 When the polymer has dried, remove all screws and open the mold. 
7.18 Using alcohol as a release agent aids this process. 
7.19 Carefully pry the mold halves apart. Gently work the halves apart using a 
flat head screw driver if necessary. (Aluminum is soft so vigorous prying will 
scar the surface.) 
7.20 Pull the molded part and spacer assembly out of the mold clam shell. 
7.21 Usc a spatula to make a small gap between the silicone part and the 
spacer. 
7.22 Bathe the spacer and silicone part with alcohol. The alcohol will facilitate 
easy removal of the silicone part from the spacer. Gently work the alcohol 
into a small space between the spacer and the silicone part. 
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7.23 Gently pull the silicone part from the spacer. Figure 5 shows the final 
molded silicone part. 
7.24 Figure 7 shows an alternate mold configuration using a spacer designed to 
make a thinner walled silicone aorta. 
7.25 Clean and dry the mold assembly. Figure 6 shows the mold with the 
silicone part. 
Figure 1: Vivitro aorta mold machined from 6016 Aluminum. Two halves joined by two 
steel dowel pins and 4 socket head hex-screws. The mold insert has a black Delrin 
handle that is removable. The mold insert is secured with 4 flat head hex-screws. All 
screws are shown on the left. 
Figure 2: Assembled mold with insert. The scre·ws have not been placed in the 
mold in this photograph. The spacer insert is not fully engaged into the mold. 
This image is for general illustrative purposes. The mold assembly process is 
very simple and intuitive. 
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Figure 3: Mettler Toledo digital scale. 
Figure 4: Cole Parmer Vacuum Chamber. 
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Figure 5: Silicone elastomer ''Aorta". The part should be virtually free of air 
bubbles. 
Figure 6: Mold with silicone part and insert. This image is for illustrative 
purposes only. 
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Figure 7: Mold with spacer and resulting silicone aorta. 
Figure 8: Thinner walled silicone aorta. 
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Figure 9: Vivitro LHS shmvn for reference. 
SOP03 
1. Title: Vivitro Systems, Inc. Superdup'r Left Heart Simulator (LHS) Valve Test 
Data Analysis Process 
2. Scope: This document is intended to describe the data analysis process for the 
purpose of creating reports that contain relevant hydrodynamic parameters for the 
evaluation of heart valve prosthesis performance. 
3. Author: Thomas E. Claibome, III 
4. Referenced Documents: 
4.1 None 
5. Materials: 
5.1 Printer paper 
5.2 Printer ink 
6. Equipment 
6.1 PC 
6.2 MatLab Software 6 or later 
6.3 Acqknowledge Software 
6.4 Microsoft Excel Spreadsheet Software 2003 or later 
6.5 Printer 
7. Acqknowledge Procedure 
7.1 Open Acqknowledge 3.7.3 
7.2 Open your baseline data file. 
7.3 Select the l-bar at the bottom right of the screen as shown in figure l. 
7.4 Go to Edit-7Select All as shown in figure 1. 
7.5 Record the values shovm in Channels 1 to 3. These are the ''K'' values that 
vvill bt: used to transfonn the waveforms in all channels. K refers to a constant 
which amounts to a correction factor that effectively zeros all of your data. 
7.6 Close the baseline data file. 
7. 7 Open a test data tile. 
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7.8 Select Transform-:) Waveform Math as shown in figure 2. 
7.9 A window called Waveform Arithmetic will open as shown in figure 3. 
7.1 0 Select CH 1 under Source 1, select ( -) under Operand, select K under 
Source 2, and select CH 1 under Destination. Enter your K-value for channel 
1 where it reads "Constant=." 
7.11 Check the box labeled ''Transform entire waveform." 
7.12 ClickOK. 
7.13 Now you have transformed channel 1. 
7.14 Repeat steps for channels 2 and 3 using the related K-values. 
7.15 Now you need to create a new waveform in channel4 that will show the 
pressure gradient across the test valve. 
7.16 Again select Transform-:) Waveform Math as shown in figure 2. 
7.17 The Waveform Arithmetic window will again open as shown in figure 3. 
7.18 This time select CH 2 under Source 1, select(-) under Operand, select CH 
1 under Source 2, select New under Destination, and check the box labeled 
"Transform entire wavefbrm" as shown in figure 4. 
7.19 Now your will see channel 4. 
7.20 Go to Display-:) Autoscale wavefonns to adjust the view. 
7.21 In the channel read-out bar select Channcl4 as shown in figure 5. 
7.22 Under channel4 select mean as shown in figure 6. 
7.23 Select File-:tSave. 
7.24 Then select File-:tSave As ... and save the file as a .txt file with a numeric 
name. 
7.25 Repeat steps for each test data file. 
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Figure 1: Screenshot of baseline data file showing where to find Edit functions. 
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Figure 2: Screenshot of test data file showing where to find the waveform math function. 
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Figure 3: Screenshot showing the \vaveform arithmetic window. 
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Figure 4: Screenshot of Waveform Arithmetic showing which values to input. 
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Figure 5: Screenshot showing where to find Channel 4 selection. 
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Figure 6: Screenshot showing where to find mean for channel4. 
8. Matlab Procedure 
8.1 Create a New Folder on the hard drive. 
8.2 Place all of your transformed .txt data f11es into the new folder. 
8.3 Copy your .m Matlab program into the new folder. 
8.4 Open Matlab 6 or later. 
8.5 Go to the Current Directory window and click the browse for folder button as 
shown in figure 7. 
8.6 Browse for your newly created folder and select it in the Browse for Folder 
window as shown in figure 8. 
8. 7 Click OK. 
8.8 Now all of your data files and the .m file are in the Current Directory as 
shown in figure 9. 
8.9 Now double-click your .m file. If you are using the .m file written by Ted 
Claiborne then continue. 
8.10 Follow the instructions written next to the code as shown in figure 10. 
8.11 Once you have changed the file names and the heart rate in the .m file 
click Run or press F5 on the key board. 
8. 12 The data used for calculation is now in your Workspace and the output 
information is now in your Command Window as shown in figure 11. 
8.13 Select the command window. 
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8.14 Select File~ Print~OK. 
8.15 Repeat steps for each data set. 
8.16 Compile all data from the print-outs into an Excel file. 
8.17 Create plots of Pressure Drop during Forward Flow as a function of Mean 
Forward Flow and Percent Regurgitation as function of Cardiac Output. 
8.18 End. 
m 1111 r 
infc. 
Figure 7: Screenshot showing where to map to a \vorking directory. 
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Figure 8: Screenshot showing where to find your working folder. 
Figure 9: Screenshot of current directory. 
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Figure 10: Screenshot of Ted Claiborne's .m file with instructions highlighted. 
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Figure 11: Screenshot of data and program output. 
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SOP04 
FlU-HYDRODYNAMICS HEART VALVE TESTING PROTOCOL 
Figure 1: Vivitro Systems, Inc Superdup'r Left Heart Simulator. 
FIU - CVEC Vivitro Superdup'r protocol by Siobhain Gallocher 
Procedure 
1. Title: Protocol for the Hydrodynamic testing of valves in the Vi vitro Superdup 'r 
SD6891: Model Left Heart and Load (figure I). 
2. Objectives: 
2.1. To ensure a reliable and repeatable method to test valve hydrodynamics in 
the Vivitro Superdup'r. 
2.2. In so doing, the hydrodynamic results from valves tested on different days 
and by different individuals can be compared. 
3. References: 
3.1. ANSI/AAMI/ISO 5840: 1996 
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4. 
3.2. FDA CDRH. 1994 
3.3. SPS3891 Operating Manual 
Procedure: 
4.1. Blood Analog Solution Preparation 
4.1.1. Prepare 2L of the blood analogue solution by combining the 
following: 720 mL Glycerine+ 1280 mL DI 1120 + 18 g NaCl 
4.1.2. Mix until solution is homogeneous(- 15 mins) 
4.2. Equipment Set-up 
4.2.1. For the Mitral position valve: 
4.2.1.1. Place the St. Jude Bileafelt valve in its silicone valve holder 
and insert it into the mitral position so that the valve opens downwards 
and iluid ilow is from the atrium into the ventricle. 
4.2.1.2. Replace and secure the left atrium assembly and associated 
tubing 
4.2.2. For the aortic position valve: 
4.2.2.1. Place the valve to be tested in its silicone valve holder. and 
orient it in position so that iluid ilow is upwards, trom the ventricle to 
the aorta. 
4.2.2.2. For trileaflet valves. be sure to orient the valve so that it is 
aligned with the sinus ofvalsalva (glass sinus). 
4.2.2.3. Orient it so that the leailets are in line with the 3 sinuses 
and the posts are aligned with the inter-sinus spaces. 
4.2.3. Fill the system with the blood analog solution prepared in 4.1 
4.2.3.1. The iluid levels are represented in Figure 1 below. 
4.2.3.2. Running the system at a low amplitude can accelerate this 
filling process 
4.2.4. 
4.2.4.1. 
Tum on the electromagnetic flow meter and press the alarm button. 
Do not tum on flowmeter unless ilow probe is submersed 
in iluid. 
4.2.4.2. Be sure to allow the flow meter to warm up for 30 mins 
prior to use 
4.2.5. Connect two catheter-tipped piezoelectric pressure transducers to 
their associated 
4.2.5.1. Handle the pressure transducers very delicately because 
small mechanical injury can result in transducer damage 
4.2.5.2. Record in the laboratory notebook the serial numbers and 
reference numbers of each of the three components (pressure 
transducer, control unit, and amplifier) and the manner/order in which 
they are connected. 
4.2.5.3. Tape the catheter tips to the acrylic top of the Superdup'r 
unit for the calibration/zeroing procedure. 
4.2.5.4. Check that the amplifier settings are as follows: Gain: 
4.3. 
4.3.1. 
5000; 300Hz LP: ON; LP: 5kHz; HP: DC 
Pressure and Flow Transducer Scaling and Zeroing 
Open the Acqknowledge 3.7.3 softv.me 
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4.3.2. 
4.3.3. 
-A3). 
Select MP 100 and then Setup Channels from the pull down menu. 
For a standard set-up, select all3 boxes for the first 3 channels (Al 
4.3.3.1. When setting up the channels, assign them as follows by 
inputting the labels in the editable text portion: 
4.3.3 Channel Al: Ventricular Pressure 
4.3.3.3. Channel A2: Aortic Pressure 
4.3.3.4. Channel A3: Aortic Flmv 
4.3.3.5. Make a note of which pressure transducer & control box is 
attached to which channel 
4.3.3.6. This is an arbitrary assignment, but once assigned, they 
must not be switched. 
4.3.3.7. Scale the pressure and flow transducers as follows: 
4.3.3.7.1. 
4.3.3.7.1.1. 
Pressure Transducers: 
Select the circular button for the Ventricular 
Pressure and click the scaling button. 
4.3.3.7.1.2. In the pop-up box that appears, enter 0 and 
100 for the two scale values, input mmHg in the Units box, 
and select the use mean value in the Options box 
4.3.3. 7.1.3. Make sure the pressure transducer control 
box for the ventricular pressure transducer is set to Standby 
and hit Call 5 times in succession. 
4.3 .3. 7 .1.4. Change the pressure transducer control box 
setting to 100 and hit the Cal2 button 5 times in succession. 
4.3.3. 7.1.5. Once completed select OK and set the 
pressure transducer control boxback to Standby. 
4.3 .3. 7 .1.6. Repeat this procedure for the Aortic 
Pressure 
4.3.3.7.2. 
4.3.3. 7.2.1. 
Flow Transducer 
Select the circular button for the Aortic 
Flow and click the scaling button. 
4.3.3.7.2.2. In the pop-up box that appears enter 0 and 1 
for the two Input Volts values, 1 and 100 for the scale 
values, and enter Llmin in the Units box 
4.3.3.7.2.3. This is the standard setting when the 
flowmeter Range is set to Hi-C. 
4.3.3.7.2.4. Once completed select OK. 
4.3.4. Close the Input Channels Box 
4.3.5. Transducer Zeroing 
4.3.5.1. For the five data analysis pull-down menus change the first 
3 to measure mean Ventricular Pressure (CHl), Aortic Pressure (CH2), 
and Aortic f1ow (CH3). 
4.3.5.2. Pressure Transducer 
4.3.5.2.1. Change the pressure transducer control box settings 
for both the ventricular and aortic pressure to transducer. 
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4.3.5.2.2. With the transducers exposed to atmosphere, select 
the start button on the bottom right of the Acqknowledge screen, 
and adjust the transducer balance until the output is approximately 
zero (± 0.05). 
4.3.5.2.3. In order to approximate this more accurately it may 
be necessary to adjust the vertical scale on the right hand side of 
the plot. 
4.3.5.2.4. Measure approximately 10 sees of data to determine 
the numerical mean value. 
4.3.5.2.5. Lock the balance in place when the pressures are 
zeroed. 
4.3.5.2.6. Once completed set the pressure transducer control 
box back to Standby. 
4.3.5.2.7. Whenever pressure transducers are not in use, the 
pressure transducer control box should be set to Standby 
4.3.5.3. Flow transducer 
4.3.5.3.1. Select the start button on the bottom right ofthe 
screen, and adjust the zero on the Flowmeter until the output is 
approximately zero(± 0.05). 
4.3.5.3.2. Measure approximately 10 sees of data to determine 
the numerical mean value. 
4.4. Flow and Pressure Transducer Calibration 
4.4.1. Flow transducer 
4.4.1.1. Flow transducer calibration must be performed every 3 
months. Refer to the Flow Transducer Calibration Protocol. 
4.4.2. Pressure transducer 
4.4.2.1. Pressure transducer calibration must be performed prior to 
any experimental measurements. 
4.4.2.1.1. Connect the Ventricular pressure transducer to the 
3-way stopcock of the pressure calibration set-up (mercury 
manometer to record pressure & sphygmomanometer bulb to 
induce pressure). 
4.4.2.1.2. Change the pressure transducer control box settings 
to transducer. 
4.4.2.1.3. With the sphygmomanometer bulb. exert 100 
mmHg while simultaneously recording the pressure with the 
Acqknowledge software. 
4.4.2.1.4. Check the mean pressure recorded with 
Acqknowledge is 100 mmHg. 
4.4.2.1.5. Repeat this for an applied pressure of 50 mmHg. 
4.4.2.1.6. If, at any stage, the recorded pressure does not 
match the applied pressure, repeat procedure 4.3.C.lii.a and then 
4.4.B.I.a-f. 
4.5. Pressure Transducer Set-up 
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4.5.1. Insert catheter-tipped piezoelectric pressure transducers into 
ventricular and aortic positions. 
4.5.1.1. For the ventricular pressure, insert the pressure transducer 
through the 3-way stop-cock as shO\vn. 
4.5.1.2. Thread the catheter through the port until it is located in the 
center of the ventricle. 
4.5.1.3. For the am1ic pressure, insert the pressure transducer 
through the 3-way stop-cock. 
4.5.1.4. Thread the catheter through the port until it is located in the 
center of the aorta. 
4.5.1.5. Keep the stop-cock open to the transducer as long as it is in 
position. DO NOT close the stop cock as this will result in damage to 
the pressure transducer. 
4.5.1.6. The stop-cock can be closed when the transducer is 
removed. Failure to close the stop-cock under these conditions will 
result in fluid loss from the system. 
4.5.2. Take baseline data 
4.5.2.1. Once transducers are in place, measure the baseline data: 
4.5.2.2. Make sure the Superpump Control Box is off. 
4.5.2.3. Using the Acqknowledge software, select the start button 
on the lower right hand side of the screen and allow it to run to 
completion (30 sees). Save the file under its valve type/lot# and entitle 
it ''Baseline" (eg. C:\My Documents\VLV 60\Baseline) 
4.5.2.4. This data will be used during data analysis. 
4.6. Experimental Measurement 
4.6.1. The standard experimental cardiac output/heart rate combinations 
are presented in. Any additional cardiac outputs can be included at the 
discretion ofthe evaluator. 
4.6.2. System Tuning 
4.6.2.1. Change the pressure transducer control box settings for 
both the ventricular and aortic pressure to transducer. 
4.6.2.2. Use the Select Wave Knob on the Waveform Generator to 
select the cardiac output required: 1: 45 BPM; 2: 70 BPM; 3: 100 
BPM; 4: 120 BPM 
4.6.2.3. Increase the amplitude on the Superpump Control Box until 
the approximate cardiac output is achieved. 
4.6.2.4. This is done iteratively. Dial up the amplitude to 
approximately 2.5 and adjust the resistance until the pressure gauge 
reads 120/80. 
4.6.2.5. Measure the cardiac output and mean aortic pressure using 
the Aqcknowledge software 
4.6.2.6. Highlight 5 waves from beginning systole to end diastole 
and measure the mean f1ow (i.e. cardiac output) and aortic pressure. 
4.6.2.7. The mean aortic pressure should be ~95 mmHg 
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4.7. 
4.6.2.8. Adjust the amplitude on the Superpump Control Box and 
the resistance, and repeat 4.6.B.III.b until the desired flow is achieved. 
4.6.2.9. Check that the Silicone Ventricle Membrane is neither 
over-inflating or -contracting 
4.6.2.1 0. If it is doing either, insert or remove air from the right port 
on the Viscoelastic Impedance Adapter. 
Once mean cardiac output and aortic pressure are set and the ventricle is 
functioning conectly, video the valve function and record a full range of data 
(30secs) by selecting the Start button. Save the data in the same folder as the 
baseline data and include the cardiac output and heart rate in the filename. 
4.7.1. Digital video recording can interfere with the flow transducer, so 
take a segment of video prior to recording any data. Switch the video 
recorder off and remove it from the area for data acquisition. 
4.7.2. For example, if a valve with Lot# TRV-VLV-0004-R060 is tested 
at 70 BPMs and 6 Llmin, it can be saved as: 
4.7.3. C:\My Documents\VLV 60\70-6 
4.7.4. Repeat 4.6.B for each of the cardiac output/heart rate 
combinations. 
Heart Rate 45 70 100 120 
2.3 3.9 6.0 7.8 
co 3.6 5.6 8.0 9.6 
5.0 7.4 10.0 11,4 
SOP 05 
TC PHV 4 SERIES FABRICATION PROCESS 
1. Title: TC PHV fabrication procedure. 
2. Author: Thomas E. Claiborne, III 
3. Scope: This document is intended to describe the process of manufacturing a TC 
PHV 4 series prototype. 
4. References: Deurig et al. 2000, Gallocher et al. 2006, \\'WW.nitinol.com 
5. Materials: 
5 .1. 5 .1. Bard OEM Components, non-sterile, P04081 polyester fabric; style: 
6102 
5.2. Small Parts, Inc. super-elastic nitinol wire, 36 inch length, 0.022 inch OD, 
0.012 inch OD 2 each 
5.3. Small Parts, Inc. XTW 304 SS Hypo-Tube 6 inch lengths, ID 0.025 inch, 
ID 0.050 inch 1 each. 
5.4. SIBS pellets 
5.5. Toluene solvent 
5.6. 4-0 Ethibond Excel braided polyester suture, 36 inch length, RB-1 taper 
needle, 4 each 
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5.7. Elmer's Krazy Glue, 1 tube 
5.8. Small Parts. Inc. 302 SS ball bearings, 3/8 inch. 3 each 
5.9. Aluminum foil 
5.1 0. Invisible tape 
5.1 L Water 
6. Equipment: 
6.1. Gallocher drying plate 
6.2. Free standing grip 
6.3. Needle driver 
6.4. Suture scissors 
6.5. Forceps 
6.6. Scalpel 
6.7. Fume Hood 
6.8. Glass Bovd 
6.9. Bubble level 
6.1 0. Furnace capable of reaching 500°C 
6.11. Claiborne nitinol annealing tixture 
6.12. C-clamps, 5 each 
6.13. Hexagonal wrenches 
6.14. Nut driver 
6.15. Furnace tongs 
6.16. Heat resistant gloves 
6.17. 5-gallon bucket 
6.18. Fabric cutter 
6.19. Small flat-head screw driver 
7. Procedure: 
7 .1. Shaping the Nitinol Wire 
7.1.1. Take the base plate of the Claiborne annealing fixture (the one 
with the pins) and clamp it to the table top using a C-clamp. 
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7.1.2. Using another C-clamp, secure the end of the 0.022 OD nitinol 
wire near the edge of the base plate. 
7.1.3. Begin threading the wire around the pins in the plate that are 
patterned to make tear drop shaped bends in tbe wire (clusters of three pins 
in a triangle). 
7.1.4. Keep the wire taught and guide it into tbe pin slots using a flat-
head screw driver. Failure to do so will allow the wire to pop out of the 
fixture. 
7.1.5. Once the entire pin pattern has been threaded, secure the end ofthe 
wire with a third C-clamp. 
7.1.6. Now repeat the procedure using two 0.012 OD nitinol wires and 
the single pin pattern that will create a sinusoidal shape. 
7.1.7. Lay each wire on top ofthe other. 
7.1.8. Place tbe top plate of the Claiborne annealing fixture onto the 
bottom plate, tltting the slots over the pins. 
7.1.9. Place the two end clamps on the bottom plate. 
7.1.1 0. Secure all plate with the screws and nuts (figure 2). 
7.1.11. Ensure that they are as tight as possible. 
Figure 2: Claiborne annealing fixture assembled with wires in place. 
7 .1.12. Place the tlxture in a cold furnace and set the temperature to 
500°C. 
7 .1.13. Once the furnace reaches 500°C let the fixture soak in the furnace 
for 5 minutes. Temperature fluctuation during the soak of +/- 20°C are 
acceptable. 
7 .1.14. During the soak fill a 5-gallon bucket with water 2/3 full. 
7 .1.15. After 5 minutes turn off the furnace, and using the tongs and heat 
gloves, carefully remove the tlxture and slowly quench it in the bucket of 
water. 
7 .1.16. Once it is cool to the touch, dry the tlxture and remove the wires. 
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7.2. Leaflet Material Preparation 
7.2.1. Perform this procedure inside a fume hood. 
7.2.2. Mix the SIBS pellets and Toluene 15% by mass such that you have 
"'about 50 ml total in a glass jar with a lid then place on a stirring machine. 
7.2 . .J. While the SIBS-toluene mixture is mixing prepare the drying plate. 
Figure 3: Gallocher drying plate and finished SIBS-polyester sheet shown. 
7.2.4. Ensure that the drying plate is clean and dry. 
7.2.5. Cut a piece of aluminum foil in the shape of the outer dimension of 
the drying plate, then from that square, cut out a hole in the shape of the 
square hole in the drying plate bracket (figure 3). 
7.2.6. Using the thin transparent tape, secure the aluminum foil gasket to 
the mirror finish side of the drying plate. Only tape the outer edges. Do not 
tape the central edge. 
7.2.7. Cut a 3x3 inch square of the Bard polyester fabric. 
7.2.8. Using the tape secure the fabric to the mirror finish side of the 
drying plate on top of the aluminum foil gasket. 
7.2.9. While taping down the fabric stretch it taught, but do not cover the 
screw holes with fabric. 
7.2.1 0. ~Using a scalpel, incise the tape/foil over each screw hole. 
7 .2.11. Place the drying plate bracket on top of the fabric and secure it 
using the screws. 
7.2.12. Using the 4 long comer screws and the bubble level, level the plate 
in the fume hood. 
7 .2.13. Using a syringe, draw up 7-8 cc of SIBS-toluene mixture. (200-250 
microns thickness will result) 
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7.2.14. Carefully pour the mixture onto the fabric, ensuring coverage of 
the entire surface. If air bubbles are present place the fixture into a vacuum 
chamber until it is debuhbled. 
7.2.15. Place a glass bowl over the plate and let it cure for 24 hours. 
7.2.16. After 24 hours prop-up an edge of the glass bowl for ventilation 
purposes and allow another 24 hours of curing time. 
7.2.17. Then remove the fabric from the plate. 
7.3. Stent Formation 
Figure 4: Nitinol wire shO\vn cut to length for stent fom1ation. 
7.3.1. Cut each wire so that there are only 6 bends on each side (figure 
4). 
7.3.2. Join the ends of the wire with about a 1 em length of hypo-tubing 
and crimp the tubing. 
7.3.3. Place the stents into the ends of an unused silicone aorta or another 
19 mm ID tube. 
Figure 5: Stents shown inside old SAs for gluing and drying. 
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7.3.4. Then add the glue to the hypo-tubing. Capillary action will draw 
the glue into the tubing. 
7.3.5. Once glue has dried, about 30 minutes, remove the stents and 
scrape off the excess glue using a scalpel. 
7.4. 
7.4.1. 
Figure 6: Assembled stents. 
Valve Assembly 
Cut a 20 em x 65 em rectangle from the SIBS-polyester sheet. 
Figure 7: Valve material cut to size. 
7.4.2. Place the sheet into the grip fixture and form the sheet into a 
cylinder ensuring that the smooth shiny side is the inside surface (figure 8). 
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Figure 8: Valve material prepared for suturing. 
7.4.3. Using an in-out purse-string style stitch secure the two overlapping 
ends of the sheet. They should over lap by about 2-3 mm (figure 9). 
Figure 9: Stitching technique shown. 
Figure 10: Final shape of valve material prior to marriage with the stents. 
7.4.4. Fold the valve material cylinder such that a 5 mm high cuff is 
made on the outside of the valve. 
7.4.5. Place the two sinusoidal stents into the cuff(figure 11). 
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Figure 11: The proximal stents in the valve cuff. 
7.4.6. Arrange the stents so that they are 180° out of phase. 
7.4. 7. Suture the crossing sections of the stents to the cuff using single 
stitches(figure 12). 
Figure 12: Suture teclmique for the proximal stents and valve. 
7.4.8. Then suture the distal edge of the valve to each of three of the 
bends of one of the stents at equal distances. i.e. out of 6 bends. every other 
bend will be secured to the distal portion of the valve material. This will 
form the trileaf1et valve (figure 12). 
7.4.9. Now secure the distal fixation stent to the distal edge of the 
proximal stent-valve assembly looping the sutures around twice between 
each of 6 bends in the distal and primal stents. Tie at least 6 knots. 
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Figure 13: Adding the fixation stent to the PHV. 
7.5. Annealing the PHV 
7.5 .1. Place the finished PHV onto the 19 mm OD SA mold insert via 
the base of the PHV (figure 14). 
7.5.2. Wedge one SS ball bearing behind each leaflet, 3 each. 
7.5.3. If needed place a large BB on top. 
7.5.4. Place the assembly in an oven set to 60°C for two hours. 
7.5.5. Remove and allow to cool before testing. 
Figure 14: Shape setting the leaflets to hemispherical shapes. 
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Figure 15: Final TC PHV 4 series design. 
Figure 16: Altemative suture technique shown on the outer cuff. A running 
stitch all the way around the bottom half of each stent bend. 
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